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Choline is an essential nutrient, which functions in cellular membrane structure, 
neurotransmission and methyl group donation. The need for choline increases 
substantially during pregnancy. An Adequate Intake (AI) for choline has been 
established at 450mg/d for pregnant women. This thesis was focused on assessing the 
influence of choline intake exceeding the current AI during the third trimester of 
pregnancy on maternal and fetal genomic readouts in humans.  
A 12-week choline controlled feeding study was conducted among third trimester 
pregnant and nonpregnant control women. The participants were randomized to either 
480mg choline/d, which is slightly above the AI, or 930mg/d. Maternal blood samples 
were retrieved at the study beginning (wk-0) and end (wk-12). Placental biopsies, and 
maternal and cord blood samples were retrieved at delivery. Epigenetic marks and 
transcriptomes were assessed.  
Genomic markers in fetal derived tissues were responsive to maternal choline 
intake. Specifically, the higher maternal choline intake group (930 vs 480 mg/d) had 
higher placental global DNA and histone methylation (P=0.02). The placental 
promoter DNA methylation of cortisol regulating genes corticotropin releasing 
hormone (CRH) (P=0.05) and glucocorticoid receptor (NR3C1) (P=0.002) were also 
 higher among women consuming 930 vs 480 mg choline/d, which was consistent with 
decreased CRH gene expression (P=0.05) in the placenta and lower cortisol in cord 
blood (P=0.07) in the 930 mg choline/d group. Analysis of the placental transcriptome 
revealed that the higher maternal choline intake group had lower expression of the 
anti-angiogenic factor soluble fms-like tyrosine kinase-1 (sFLT1) (P=0.05), a marker 
that predicts preeclampsia. Similar decreases (P=0.04) were detected in maternal 
blood sFLT1 protein concentrations. The effect of choline on decreasing sFLT1 was 
confirmed in a trophoblast cell line HTR-8/SVneo. Additionally, in this cell line, 
suboptimal choline concentrations in the culture medium induced apoptosis, elevated 
oxidative stress, increased expression of angiogenic and inflammatory genes, and 
impaired in vitro angiogenesis. Inhibition of protein kinase C rescued the effects of 
low choline on angiogenesis and apoptosis indicating that choline deficiency perturbs 
this signaling pathway.  
In sum, a maternal choline intake exceeding current recommendations may 
beneficially program offspring stress reactivity and mitigate the production of proteins 
associated with preeclampsia.  
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PREFACE 
INTRODUCTION AND SIGNIFICANCE: 
Choline, an essential nutrient often grouped with the B vitamins, is a precursor of the 
membrane constituent phosphatidylcholine, the neurotransmitter acetylcholine, and the 
methyl donor betaine (1). These choline biomolecules participate in various biological 
processes including growth and development, neurotransmission and one-carbon metabolism 
(2, 3). 
The demand for choline increases substantially during pregnancy as both placental 
expansion and fetal development require a large amount of choline to support membrane 
biosynthesis and accelerations in one-carbon metabolism (4). Babies are born with up to five 
times higher plasma free choline concentrations than their mothers (5), which facilitates 
choline uptake by the developing brain (6). In rodents, provision of extra choline (i.e., 4 times 
higher than normal) during the last half of gestation improves spatial memory and prevents 
age-related cognitive deficits in the adult offspring (7). Maternal choline supplementation of 
the dam diet during gestation can also delay the progression of chemically-induced breast 
cancer in the female offspring (8). 
The dietary requirement for humans is unknown and recommendations are provided in 
the form of adequate intakes (AIs). The choline Adequate Intake (AI) for pregnant women of 
450 mg/d was designed to prevent liver dysfunction (9) which arises from insufficient 
amounts of choline to synthesize very low density lipoproteins. Given the many other roles 
of choline in human health, studies are needed to address the impact of maternal choline 
intake during pregnancy on a wider array of metabolic markers and physiologic 
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processes.  
Metabolic and physiological alterations often involve changes in the genomic landscape 
and prior work has shown that choline intake can affect several genomic endpoints including 
epigenetic modifications (e.g. DNA and histone methylation) (10, 11), DNA damage (12) and 
genome-wide gene expression (13). As such, it is important to understand the genomic 
implications of varied maternal choline intake during pregnancy as it may have lasting effects 
on maternal health as well as fetal development and metabolic functioning. Ultimately, these 
data can be used to scientifically inform development of dietary choline intake 
recommendations that support the health and well-being of both mother and child.  
To facilitate the discovery of metabolic and physiologic processes influenced by maternal 
choline intake, the primary goal of my dissertation was to investigate the response of 
genomic markers to maternal choline intake. A secondary goal was to investigate the 
effect of pregnancy on genomic markers. To achieve these goals we conducted a controlled 
feeding study in which pregnant (n=26, gestational week 26-29) and nonpregnant (n=21) 
women were randomized to choline intakes of 480 mg/d (slightly above the AI) or 930 mg/d.  
The 7-day rotational diet, consumed by all women, provided 380 mg choline/d.   
Supplemental choline chloride, 100 or 550 mg/d, was used to achieve the target choline 
intake levels. Blood was collected throughout the feeding phase from both pregnant and 
nonpregnant women. Maternal and cord blood samples along with the placenta were obtained 
at delivery (14). 
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SPECIFIC AIMS: 
Aim 1: To test the hypothesis that maternal choline intake during the third trimester of 
pregnancy influences epigenetic and epigenomic markers in fetal derived tissues. This 
aim was achieved by measuring placental and cord blood global DNA and histone 
methylation, as well as site specific methylation patterns of genes with key roles in fetal 
development and are regulated by DNA methylation. 
Results are presented in chapter 1. 
 
Aim 2. To test the hypothesis that maternal choline intake during the third trimester of 
pregnancy influences the placental transcriptome.  This hypothesis was tested by 
assessing the placental gene expression changes in response to maternal choline intake using 
genome-wide expression microarray. Genes and physiological processes of particular interest 
were further analyzed at protein level and in a trophoblast culture model.  
Results are presented in chapter 2.  
 
Aim 3. To test the hypothesis that maternal choline intake and/or pregnancy affects 
maternal blood leukocyte genomic markers. This aim was achieved by measuring DNA 
damage, global DNA and histone methylation, and genome-wide gene expression patterns in 
blood samples obtained from pregnant and nonpregnant women.  
Results are presented in chapter 3.  
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This dissertation research yielded three published peer-reviewed articles (Chapters 1 - 3) 
and one original research manuscript, which will be submitted for publication within the next 
few months (Appendix A).   
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BACKGROUND AND RATIONALE: 
Choline metabolism and function 
The three major metabolic fates of choline are synthesis of phosphatidylcholine, oxidation 
to betaine and acetylation to acetylcholine. Through these metabolic pathways, choline 
participates in various physiological functions throughout the body (Figure P.1). 
 
 
 
 
 
 
 
 
 
 
Figure P.1. Choline metabolism and function. There are three major metabolic fates of 
choline - synthesis of acetylcholine, betaine and phosphatidylcholine. Key enzymes 
involved in the choline metabolic pathways are shown next to the arrows which indicate 
chemical reactions. Major functions of the choline metabolites are listed in the boxes. 
Abbreviations: BHMT, betaine homocysteine S-methyltransferase; CHAT, choline 
acetyltransferase; CHDH, choline dehydrogenase; CT, CTP:phosphocholine 
cytidylyltransferase; PEMT, phosphatidylethanolamine N-methyltransferase; SAM, 
S-adenosylmethionine. 
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Phosphatidylcholine 
Phosphatidylcholine is synthesized via the cytidine diphosphate-choline (CDP-choline) 
pathway from an intact choline molecule or via the phosphatidylethanolamine 
N-methyltransferase (PEMT) pathway from phosphatidylethanolamine and SAM derived 
methyl groups (15). CTP:phosphocholine cytidylyltransferase (CT) and PEMT are the rate 
limiting enzymes of these pathways, respectively. Although the PEMT pathway is considered 
a de novo pathway for choline biosynthesis, it is notable that PEMT uses choline derived 
methyl groups to make a new choline moiety (16) and that a higher choline intake can 
upregulate this pathway in nonpregnant women (West et al. in press). As such, maternal 
choline intake can affect the synthesis of phosphatidylcholine via both biosynthetic pathways 
and therefore its availability for the biological processes outlined below. 
  As a major phospholipid in cellular membranes, phosphatidylcholine is essential for 
cell division and tissue expansion (17, 18) as well as membrane integrity. A diminished 
presence of phosphatidylcholine in mitochondrial membranes leads to the leakage of free 
radicals, oxidative stress and DNA damage (19, 20). Phosphatidylcholine is also an 
indispensable component of very low density lipoproteins (VLDLs) and phosphatidylcholine 
deficiency results in fatty liver due to the inability to export fat (21). Finally, 
phosphatidylcholine is a source of several signaling molecules (e.g., diacylglycerol, 
phosphocholine, phosphatidic acid and glycerophosphocholine) that can influence a wide 
range of physiologic processes including proliferation, differentiation, cell cycle and 
apoptosis (22). 
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Betaine 
Choline is oxidized to betaine via a two-step reaction initiated by choline dehydrogenase 
(CHDH). The oxidation of choline to betaine diverts choline towards the one carbon cycle, 
which mediates the transfer of methyl groups (23). Specifically, in liver and kidney, one of 
the labile methyl groups from betaine is transferred to homocysteine by betaine: 
homocysteine S-methyltransferase (BHMT), forming methionine. The methionine produced 
by the reaction is then converted to S-adenosylmethionine (SAM), the universal methyl donor 
required for methylation reactions (24). As such, choline derived methyl groups are used to 
synthesize over 60 metabolites including phosphatidylcholine (via PEMT) and to methylate 
DNA and histones (25).  
 
Acetylcholine 
The acetylation of choline to acetylcholine is catalyzed by choline acetyltransferase 
(CHAT). Acetylcholine can serve as a signaling molecule in neuronal and non-neuronal 
tissues by binding to nicotinic or muscarinic acetylcholine receptors (26, 27). In the neuronal 
system, acetylcholine serves as a neurotransmitter for cholinergic neurons. In some 
non-neuronal organs, such as the placenta, acetylcholine is present in large amounts and may 
function in vascular dilation, amino acid transport and placental differentiation (27, 28).  
 
Interactions between choline and genomic biomarkers 
Epigenetic modifications 
Epigenetic marks (e.g., DNA and histone methylation) are heritable modifications on the 
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genome that do not change DNA sequences (29). The most common form of DNA 
methylation is the addition of a methyl group to the C-5 position of cytosine within the 
context of a cytosine phosphate guanine (CpG) dinucleotide. Although 60-90% of all CpG 
sites in mammal genomes are methylated (30), the promoter region of most housekeeping 
genes contains a high frequency of CpG sites that are usually not methylated (i.e. CpG 
islands), which allows for transcription factor access and transcription procession. Often but 
not always, CpG island methylation leads to transcription suppression. Histone modification, 
the alkaline proteins which DNA wraps around, is another common epigenetic mark which 
can influence accessibility of transcription factors to their binding sites (31) and ultimately 
gene expression. For example, methylation of histone 3 lysine 9 (H3K9) associates with   
heterochromatin formation and the suppression of DNA transcription (31).  
The epigenetic state of the human genome is modulated by environmental exposures 
(e.g., nutrients) especially during critical windows of development like the prenatal period. 
Epigenetic modifications occurring during the prenatal period can permanently modify 
physiological functions with subsequent effects on chronic disease risk including Type 2 
diabetes (32), hypertension (33) and cancer (34).  
Maternal choline intake during pregnancy has been shown to affect the fetal epigenome 
presumably through its role as a methyl donor. For example, prenatal choline deficiency 
decreased hippocampal DNA and histone methylation (35, 36), which resulted in reduced 
hippocampal angiogenesis. In addition, prenatal choline supplementation decreased DNA 
methylation of a tumor suppressor gene and delayed the progression of chemically induced 
breast cancer in the female offspring (8).  
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DNA damage 
Lesions that compromise the integrity of DNA molecules include single or double strand 
breaks, base modification, and DNA-protein crosslinks (37). Unresolved DNA damage 
decreases genomic stability, which results in aberrant gene expression, apoptosis and/or 
necrosis. One of the major causes of DNA damage is oxidative stress, a condition that arises 
when the amount of reactive oxygen species (ROS) released by mitochondria exceeds the 
balancing capabilities of the cellular antioxidant system. Under these conditions, surplus ROS 
react with DNA, causing its damage (38). In turn, the level of DNA damage indicates the 
severity of oxidative stress. Pregnant women have a higher susceptibility to oxidative stress 
mostly because that the human placenta is enriched with mitochondria (39). As such, DNA 
damage may serve as a sensitive genomic marker to advance understanding of redox balance 
during normal pregnancy.  
In addition, given choline’s role in maintaining the integrity of the mitochondrial 
membrane, DNA damage may serve as a functional indicator of choline status. In this regard, 
studies in hepatic cell lines and rodents have consistently demonstrated that choline 
deficiency increases DNA strand breaks and cellular apoptosis of hepatocytes (20). In 
humans, consumption of a choline deplete diet for 42-d increased the level of lymphocyte 
DNA damage and apoptosis as compared to baseline values (19). Similarly, consumption of a 
higher choline intake (i.e, 2200 versus 550 mg/d) among folate compromised men lowered 
the level of lymphocyte DNA damage (10).  
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Messenger RNA synthesis 
Transcription of DNA to messenger RNA can influence gene expression with downstream 
effects on physiological processes. Choline intake may influence mRNA synthesis via its role 
as a methyl donor and/or signaling molecule. Notably, consumption of a choline deficient diet 
for 6 weeks by healthy men and women altered lymphocyte transcription of genes related to 
cell cycle, methylation, apoptosis and cell growth as compared to baseline values (13). 
Additionally, supplementing the rodent maternal diet with extra choline during pregnancy 
altered the transcriptome of the female offspring with a profile consistent with better tumor 
prognosis (8).  
 
Conclusions 
There is a wealth of evidence from animal studies (and a few human studies) that choline 
intake can influence genomic readouts. Nonetheless, the effect of maternal choline intake 
during human pregnancy, a critical window of development, on genomic marks is unknown. 
As part of a controlled feeding study in third trimester pregnant women, this dissertation 
employed targeted and non-targeted approaches to examine the impact of maternal choline 
intake on DNA and histone methylation, mRNA abundance, and DNA damage in maternal 
and fetal derived tissues. Data generated from this dissertation are expected to guide the 
refinement of choline intake recommendations during pregnancy and ultimately improve 
human health.    
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CHAPTER 1 
Maternal choline intake alters the epigenetic state of fetal cortisol regulating genes in 
humans* 
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ABSTRACT 
The in utero availability of methyl donors, such as choline, may modify fetal epigenetic 
marks and lead to sustainable functional alterations throughout the lifecourse. The 
hypothalamic-pituitary-adrenal (HPA) axis regulates cortisol production and is sensitive to 
perinatal epigenetic programming. As an extension of a 12-week dose-response choline 
feeding study conducted in third trimester pregnant women, we investigated the impact of 
maternal choline intake (930 versus 480 mg/d) on the epigenetic state of cortisol regulating 
genes, and their expression, in placenta and cord venous blood. The higher maternal choline 
intake yielded: higher placental promoter methylation of the cortisol regulating genes, 
corticotropin releasing hormone (CRH) (P=0.05) and glucocorticoid receptor (NR3C1) 
(P=0.002); lower placental CRH transcript abundance (P=0.04); lower cord blood leukocyte 
promoter methylation of CRH (P=0.05) and NR3C1 (P=0.04); and 33% lower (P=0.07) cord 
plasma cortisol. In addition, placental global DNA methylation and dimethylated histone H3 
at lysine 9 (H3K9me2) were higher (P=0.02) in the 930 mg choline/d group as was the 
expression of select placental methyltransferases. These data collectively suggest that 
maternal choline intake in humans modulates the epigenetic state of genes that regulate fetal 
HPA axis reactivity as well as the epigenomic status of fetal derived tissues. 
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INTRODUCTION 
  Nutrients such as choline, betaine and folate provide methyl groups for cellular 
methylation reactions. In animal models, the maternal consumption of these methyl donors 
modifies fetal epigenetic marks (e.g. promoter region DNA and histone methylation) (2-5) 
and leads to sustainable functional alterations throughout the lifecourse (6, 7). Nevertheless, 
evidence of fetal epigenetic modification by maternal consumption of methyl donors in 
humans is lacking.  
Our research group recently conducted a 12-wk dose-response choline feeding study in 
which pregnant women (gestational age wk 26-29) were randomized to choline intakes of 
480 [approximating the Adequate Intake (AI) for choline] or 930 mg/d throughout their third 
trimester. We found that a higher maternal choline intake increased the use of choline as a 
methyl donor as evidenced by elevations in maternal and fetal plasma dimethylglycine, the 
metabolite produced when choline is used as a methyl donor (9). The increased use of choline 
as a methyl donor may alter the epigenetic state of genes regulated by methylation as 
previously shown in animal studies (3, 4).   
 The methylation state of the cortisol regulating genes, corticotropin releasing hormone 
(CRH) and nuclear receptor subfamily 3, group C, member 1 (NR3C1), may be particularly 
sensitive to prenatal and early postnatal exposures (1, 2, 10, 11). These genes encode 
components of the hypothalamic-pituitary-adrenal (HPA) axis, which have important roles in 
stress response, immunity and glucose metabolism. In response to stress, the hypothalamus 
produces CRH which stimulates the secretion of adrenocorticotropic hormone from the 
anterior pituitary and subsequently glucocorticoids (e.g. cortisol) from the adrenal gland. 
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NR3C1 encodes the glucocorticoid receptor which plays a critical role in central HPA 
inhibition via glucocorticoid negative feedback (12). The programming of the HPA axis 
through promoter region methylation of CRH and NR3C1 may have implications for 
susceptibility to stress-related (i.e., autoimmune disorders and mental health disturbances) 
(13, 14) and metabolic (e.g. hypertension and diabetes) diseases later in life (15, 16).  
 As an extension of our 12-week dose-response choline feeding study conducted in third 
trimester pregnant women (9), this study investigated the influence of maternal choline intake 
(480 vs. 930 mg/d) on the epigenetic state of cortisol regulating genes, and their expression, 
in placenta and cord venous blood. As varied maternal choline intake may systematically 
affect a wide-array of placental genes regulated by DNA and histone methylation, four 
additional genes for site specific methylation measurements were targeted: insulin-like 
growth factor 2 (IGF2), leptin (LEP), guanine nucleotide binding protein, alpha stimulating, 
antisense transcript (GNAS-AS1), and interleukin 10 (IL10). Selection of these genes was 
based on prior evidence of methylation regulation, susceptibility to nutritional exposures, and 
associations with chronic disease risk (17, 18). Finally, given that prenatal choline exposure 
alters epigenomic readouts in animal models (3, 5), global DNA and histone methylation 
were measured.   
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MATERIALS AND METHODS 
Study Participants 
Healthy third trimester (wk 26-29 gestation) singleton pregnant women aged ≥ 21y were 
recruited from Ithaca, New York, and surrounding areas between January 2009 and October 
2010. During the screening phase, all study volunteers completed a questionnaire which 
queried participants on their age, education, work status, ethnicity/race, pre-pregnancy body 
mass index, parity, health history, medication and nutritional supplement use, and physical 
activity. Entry into the study was contingent upon good health status (i.e., no chronic diseases, 
normal kidney and liver function, and non-anemic). Additional inclusion criteria included: no 
tobacco or alcohol product use, and a willingness to comply with the study protocol. For those 
who were included in the study, information on gestational weight gain, health insurance, 
mode of delivery, obstetrical complications, and newborn sex and health characteristics were 
obtained from medical charts after delivery. Twenty-six of the 29 pregnant women who 
started the study completed it. Of the 26 women completing the study, placental samples were 
retrieved from 24 participants (n = 12/ choline intake group) and cord blood samples were 
retrieved from 23 participants. The study protocol was approved by the IRB for Human Study 
Participant Use at Cornell University and at Cayuga Medical Center (Ithaca, NY, USA). 
Written informed consent was obtained from all the participants prior to study entry. The 
study was registered at clinicaltrials.gov as NCT01127022. Additional information regarding 
the study participants is described elsewhere (9). 
Study Design and Diet 
This was a 12-wk controlled feeding study in which pregnant women were randomized to 
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either 480 (approximating the choline adequate intake (AI); n=12) or 930 (n=12) mg 
choline/d. The choline was derived from the diet (380 mg/d) plus supplemental choline 
chloride (either 100 or 550 mg choline/d for the 480 or 930 mg/d intake levels, respectively). 
During the last 6-wk of the study, ~20% of the total choline intake was provided as deuterium 
labeled trimethyl d9-choline (Cambridge Isotope Laboratories, Andover, MA, USA). 
Throughout the 12-wk study, the participants consumed a 7-day cycle menu as detailed in 
Yan et al. (9). All food and beverage were provided by the investigators and one meal per day 
was consumed on-site throughout the week. All other meals and beverages were provided as 
take-aways. In addition to the supplemental choline, a prenatal multivitamin (Pregnancy Plus, 
Fairhaven Health, LLC, Bellingham, WA, USA) and DHA (200 mg; Neuromins, Nature's 
Way Products, Lehi, UT, USA) were provided daily; a potassium and magnesium supplement 
(General Nutrition Corp, Pittsburgh, PA, USA) was provided three times per week. The 
supplements were consumed with the on-site meal under the supervision of the investigators. 
At the end of the study, participants continued on their choline supplement until the delivery 
of their babies. 
Sample collection 
Fasting (10 h) venous blood samples were obtained at baseline (wk 0) and at the end of 
the study (wk 12) in 10mL EDTA tubes (Vacutainer; Becton Dickinson, Franklin Lakes, NJ, 
USA). A maternal EDTA-blood sample was also obtained within 24 h of delivery and cord 
venous EDTA-blood was collected immediately after delivery, processed and stored as 
previously described(9). The placenta samples (n=21) were processed within 10-30 minutes 
after the delivery of the babies, except for three cases (n=2 in the 930 and n=1 in the 480 mg 
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choline/d groups, 60-90 minutes after delivery) in the hospital. Samples collected 60-90 
minutes after delivery did not alter sample quality, e.g. RNA integrity. After removing the 
amniotic sac, the placenta was visually divided into four quadrants. Full thickness biopsies 
(0.5cm*0.5cm*placenta depth) were obtained from the center of each quadrant, rinsed with 
PBS and either flash frozen in liquid nitrogen or immersed in RNAlater (Qiagen, Valencia, 
CA, USA). The samples were stored at -80C until subsequent analysis. For the DNA, 
metabolite and histone measurements, one tissue biopsy from each quadrant was pooled and 
ground in liquid nitrogen. For RNA extraction, one tissue biopsy from one of the quadrants 
was homogenized. As the placenta is a heterogeneous tissue, the results obtained from our 
experiments represent an average effect of maternal choline intake on a subset of the 
placental cells. 
Analytical Measurements 
Cortisol concentration 
   The relative intensity of maternal and umbilical cord plasma cortisol was initially 
measured by LC-MS as part of a metabolite panel by a diagnostics and services company 
Metabolon (Durham, NC, USA). The actual concentrations of cortisol (μg/dL) were later 
quantified in house using a commercially available ELISA kit (Diagnostic Automation, 
Calabasas, CA, USA) according to the manufacturer’s instructions.  
Site specific methylation  
Site specific methylation was analyzed using base-specific cleavage and mass 
spectrometry (19). The loci of interest included regions in the promoters of CRH, GNAS-AS1, 
LEP and IL10 (17); the 5’ untranslated exon 1F (and flanking regions) of NR3C1 (1); and a 
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part of the differentially methylated region 0 (DMR0) of IGF2 (20, 21). Genomic DNA was 
extracted via the DNeasy blood & tissue kit (Qiagen) and 1 μg extracted DNA was 
bisulfite-treated using the EZ 96-DNA methylation kit (Zymo, Irvine, CA, USA). DNA 
sequences of interest were PCR amplified using the bisulfite-treated DNA as the template and 
published primers (1, 17) that incorporate the T7 tag (Supplemental Table S1.1). The 
amplification products were analyzed with the MassArray EpiTYPER system (Sequenom Inc, 
San Diego, CA, USA) at the Cornell Life Sciences Core Laboratories Center (Cornell 
University). Briefly, the PCR products were in vitro transcribed by T7 polymerase, digested 
by RNase A and measured via matrix assisted laser desorption ionization/time of flight mass 
spectrometry. Percent methylation of the cytosine residues was determined for each 
cytosine-phosphate-guanine (CpG) unit, which may contain one or multiple adjacent CpG 
dinucleotides (CpG sites) that cannot be resolved individually by EpiTYPER. The CpG sites 
belonging to a particular CpG unit of each gene are shown in Supplemental Table S1.2. Only 
CpG units with measurement success rates of > 75% were included in the final analyses 
(Supplemental Table S1.3) (17).  
RNA extraction and quantitative real-time PCR 
RNA was extracted via a commercially available kit (RNeasy Mini kit, Qiagen) from 
placental tissues. The concentration and purity of the isolated RNA were assayed with 
NanoDrop® ND-1000 instrumentation (Thermo, Wilmington, DE, USA). All of the samples 
had RNA concentrations >300 ng/μL and A260/280 ratios of >2.0, indicating adequate 
quantity and purity, respectively. The quality of RNA samples was verified by agarose gel 
electrophoresis which showed discreet 18S and 28S ribosomal RNA bands. Reverse 
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transcription was performed via the ImProm-II Reverse Transcription SystemTM (Promega, 
Madison, WI, USA). The reaction conditions were: 25 oC for 10min, 42 oC for 40min, 95 oC 
for 5 min and quenching at 4 oC for 5 min. Gene transcript abundance of CRH and NR3C1, as 
well as certain DNA and histone methyltransferases [i.e., DNA 
(cytosine-5-)-methyltransferase 3 alpha (DNMT3A), DNA (cytosine-5-)-methyltransferase 3 
beta (DNMT3B), DNA (cytosine-5-)-methyltransferase 1 (DNMT1), euchromatic 
histone-lysine N-methyltransferase 2 (EHMT2) and suppressor of variegation 3-9 homolog 1 
(SUV39H1)] were analyzed by quantitative real-time PCR with the SYBR® Green system in a 
Roche LightCycler480® machine (Roche, Basel, Switzerland). The reaction conditions were 
as follows: 95 oC for 5 min, followed by 40 cycles with 15 s at 95 oC, 20 s at 60 oC and 20 s at 
72 oC. Data were expressed as the fold change of the gene of interest relative to the 
housekeeping gene (22), glyceraldehyde-3-phosphate dehydrogenase (GAPDH). All primers 
were designed using GeneRunner Version 3.01. The primers are:  
CRH, F 5'-TGAAACATAGAGGGAGAGAGGG-3',  
R: 5'-ACCTGGAAACGGAAACTAAACG-3'; 
NR3C1, F: 5’-TACCTAACGCCCTATTTTTGCA-3’,  
R: 5’-AGCTGGTTATCTGGAATCACAA-3’;   
DNMT3A, F: 5’-ACGGCAAATTCTCAGTGGTG-3’,  
R: 5’-GGACCTCGTAGATGGCTTTG-3’;   
DNMT3B, F: 5’-CAAACCCAACAACACGCAAC-3’,  
R: 5’-CAGCTGTGCGTCTTCGAGTC-3’;   
DNMT1, F: 5’-GTGTGGGAAATGTAAAGCCTGC-3’,  
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R: 5’-TCATCGTCATCTGCCTCCTTCA-3’;   
EHMT2, F: 5’-AGACAGAGCGAGGGTTTGAGG-3’,  
R: 5’-AGCTCTCCGTCCACACTCTCA-3’;   
SUV39H1, F: 5’-ATAGACAACCTTGACGAGCGG-3’,  
R: 5’-GGGTCCACTTGCATGTTGTAA-3’;   
GAPDH, F: 5’-TGTTGCCATCAATGACCCCTT-3’,  
R: 5’-CTCCACGACGTACTCAGCG-3’ 
Global DNA methylation   
Global DNA methylation was measured in placental tissues, cord blood leukocytes and 
maternal leukocytes (wk 0 and wk 12) via LC-MS/MS as described by Song et al. (23) with 
modifications based on our instrumentation (24). Briefly, DNA was extracted with the 
DNeasy blood & tissue kit (Qiagen) and digested with nuclease P1 (Sigma-Aldrich, St.Louis, 
MO, USA), phosphodiesterase 1 (Sigma-Aldrich) and alkaline phosphatase (Sigma-Aldrich). 
Hydrolyzed DNA was separated and analyzed with a LC-MS/MS system consisting of a TSQ 
Quantum mass spectrometer with electrospray ionization source operated in positive ion 
mode (Thermo, ), a refrigerated Accela autosampler (Thermo), and an Accela pump with 
degasser (Thermo). Global DNA methylation [5-methyl-2'-deoxycytidine (5mdC)] is 
expressed as a percentage of 2’-deoxyguanosine (representing total 2’-deoxycytidine). 
Isotopic enrichment (deuterium labeled d3-5mdC) is expressed as a percentage of total 5mdC 
(labeled and unlabeled metabolite). Natural isotopic enrichment and background noise was 
addressed by subtracting the signal obtained from control placental samples that were not 
exposed to labeled choline.  
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Global histone methylation  
Global histone methylation marks di-methylated histone H3 at lysine 4 (H3K4me2), 
di-methylated histone H3 at lysine 9 (H3K9me2) and tri-methylated histone H3 at lysine 27 
(H3K27me3) were measured using western blot analysis. Histone proteins were extracted 
from 100 mg frozen placental tissue and 200 μL of maternal buffy coat. Samples were 
incubated in 1 mL lysis buffer (40 mM sodium citrate, 1% Triton X-100) for 10 min and then 
centrifuged at 2000 rpm for 10 min at 4°C. The pellet was resuspended in 0.2 N hydrochloric 
acid at a cell density of 4 × 107 /mL and incubated at 4°C overnight. Samples were 
centrifuged again. Total protein concentrations of the supernatant were quantified by the 
Bradford assay (Thermo), and histone bands were visualized by SDS-PAGE and coomassie 
blue staining to ensure the presence of histones before western blot analysis. The extracts 
were separated by SDS-PAGE and transferred to Immobilon-FL polyvinylidene fluoride 
transfer membranes (Millipore, Billerica, MA, USA). Membranes were blocked in Odyssey 
blocking buffer (LI-COR, Lincoln, NE, USA) and incubated overnight with anti-H3K4me2 
(GeneTex, Irvine, CA, USA), anti-H3K9me2 (Abcam, Cambridge, MA, USA), 
anti-H3K27me3 (GeneTex) and anti-Histone 3 (Abcam) antibodies. Secondary antibodies 
were either IRDye 800CW Goat Anti Rabbit or IRDye 680 Goat Anti mouse (LI-COR), 
depending on the primary antibodies. Target protein bands were visualized and quantified 
using the LI-COR Odyssey® imaging system (LI-COR) and expressed as the ratio of 
intensity of the histone epigenetic mark to total histone 3 protein (5). 
S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) measurements 
SAM and SAH measurements were performed using the method described by Kim et al. 
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(25) with modifications based on our LC-MS/MS instrumentation. Briefly, 50 mg of placental 
tissue was mixed with d3-SAM (CDN isotopes, Pointe-Claire, Quebec, Canada) and d4-SAH 
(Cayman Chemical, Ann Arbor, MI, USA) as internal standards and homogenized in 300μL 
of 25mM ammonium acetate. The homogenate was treated with 250μL of 1N perchloric acid 
and centrifuged at 12,000×g for 10min at 4oC. An aliquot of the supernatant (550μL) was 
neutralized with 300μL of 1M ammonium hydroxide. The neutralized samples were applied 
to the Sep-Pak® Vac C18 cartridge (Waters, Milford, MA, USA) preconditioned with 1mL 
methanol, 750μL of 0.1N NaOH and 1mL water. The samples were washed with 1mL water 
and eluted with 1 mL 85:15 water: methanol (vol: vol) with 0.1% formic acid. The eluent was 
dried in a speed vacuum and re-dissolved in 150μL 0.05M ammonium formate with 0.1% 
formic acid. Analyses were conducted with the LC-MS/MS instrumentation described in the 
global DNA methylation section. Compounds of interest were separated by HPLC using a 
Luna C18(2) column (250×4.6mm, 5µm) (Phenomenex, Torrance, CA, USA) with matching 
guard column (4×3mm). The mobile phase containing acetonitrile and 0.1% formic acid in 
0.05M ammonium formate was run in a rate of 500µL/min with 2% acetonitrile for 4min, a 
linear gradient from 2% to 80% acetonitrile for 7min, followed by a return to 2% acetonitrile 
over the next 4min. The mass spectrometer was operated in positive-ion mode using 
electrospray ionization. The metabolites of interest were detected in a multiple reaction 
monitoring mode with the following transitions: SAM, m/z 399→250; d3-SAM 402→250; 
d4-SAH, m/z 385→136; SAH-d4, m/z 389→136. Quantification of SAM and SAH was 
performed by comparing samples with the signals obtained from the standards using Xcalibur 
software (Thermo).  
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Statistical analysis 
Student’s t-tests (for continuous dependent variables) and Chi-square tests (for categorical 
variables) were performed to test for differences between the choline intake groups at baseline 
and at delivery.  
General linear models (GLMs) were constructed to assess the effects of maternal choline 
intake (independent variable) on the dependent variables (e.g. cord plasma cortisol 
concentration, placental gene transcript abundance, and global DNA and histone 
methylation).  
For the site specific CpG methylation data, GLMs were constructed to analyze the effects 
of maternal choline intake on the average CpG methylation of each gene (i.e., the mean 
methylation levels of all the CpG units). To explore the effects of maternal choline intake on 
individual CpG units, mixed models were run. The mixed models included choline intake, all 
the CpG units (e.g. CpG unit A, CpG unit B, etc) within the region of interest, and the 
two-way interaction between the CpG units and choline intake as fixed factors. Participant 
identifier was included as a random factor. The analyses were followed by individual 
contrasts assessing the effect of choline on each CpG unit.  
Candidates for entry as covariates into the GLMs and mixed models are listed in Table 
1.1 and Table 1.2. To adjust for the potential influence of circadian rhythm, time of delivery 
was included as an additional covariate. The covariates not achieving a statistical significance 
of P < 0.1 were removed from the models in a stepwise process. Baseline measures (wk 0) 
were also entered into the models as covariates for maternal DNA and histone methylation. 
To account for batch effect, batch was included in the models as a covariate if the 
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measurements of a variable were done in multiple runs. All two-way interactions between the 
covariates and maternal choline intake were tested in the models. Covariates retained in the 
final statistical models are specified following the presentation of the P values. 
In addition, paired t-tests were employed to assess differences in global DNA 
methylation among tissues. Pearson’s correlation coefficient (r) was used to examine the 
association of the methylation levels among the different tissues and between the different 
epigenomic marks.  
Plots and histograms of the residuals were used to assess normality and variance 
homogeneity in the models. Dependent variables deviated from the normal distribution (e.g. 
placental gene transcript abundance) were logarithmically transformed to meet the 
assumption of normality. Differences between choline intake groups were considered to be 
significant at P ≤ 0.05; P < 0.10 was considered to be indicative of trends. Values are 
presented as means ± SEM. If covariates were retained in the final model, the values 
presented are predicted means; P values are two-tailed. All analyses were performed using 
SPSS (release 18.0 for Windows, SPSS Inc, Chicago, IL). 
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Table 1.1   
Baseline characteristics of singleton third trimester pregnant women prior to randomization to 
480 or 930 mg choline/d  
 
Baseline characteristics 480 mg/d 930 mg/d 
Number of subjects 12 12 
Age, yr (range) 29 (25-33) 28 (22-34) 
Pre-pregnant BMI, kg/m2 (range) 23.6 (20.2-31.9) 23.4 (19.9-29.8) 
Parity, primiparas/ multiparasa 8/4 3/9 
Gestational age, week 27 (26-29) 27 (26-28) 
Ethnicity, Caucasian/African American/  
Latino/ Asian/ Other 
8/0/2/1/1 6/1/2/3/0 
Physical activity, usual daily activity/  
  exercise > 3 times per wk/ unknown 
4/8/0 1/9/2 
Education, high school and college/  
  university level 
1/11 4/8 
Work status, not employed/ employed 2/10 2/10 
Health Insurance, government subsidized/  
private/ unknownb 
2/8/2 4/8/0 
 
aP < 0.05, Chi-square test; bThis parameter served as a surrogate of income. Eligibility for 
government subsidized insurance implied a relatively lower income.  
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RESULTS 
Mother and neonate characteristics 
At baseline, maternal characteristics of the third trimester pregnant women did not differ 
(P = 0.14 – 0.99) between the choline intake groups (i.e., 930 versus 480 mg/d) with the 
exception of parity (i.e., there were more primiparous women in the 480 mg choline/d intake 
group; P = 0.04) (Table 1.1). All babies were delivered without major complications and were 
apparently healthy. Mode of delivery, gestational age at birth, infant sex, infant birth weight 
and Apgar score did not differ (P = 0.11 – 0.79) between the choline intake groups (Table 
1.2). 
 
Table 1.2 
Maternal and neonatal characteristics at delivery for pregnant women consuming 480 or 930 
mg choline/d throughout the third trimester 
 
Characteristics 480 mg/d 930 mg/d 
Mode of delivery, caesarean section/ vaginal 3/9 2/10 
Gestational age at birth, wk (range) 40 (39-42) 40 (39-40) 
Infant sex, female/ male 3/9 4/8 
Infant birth weight, kg 3.4 ± 0.1 3.4 ± 0.1 
Infant Apgar score 8-9; 9 8-9; 9 
 
Cord plasma cortisol 
Cord plasma cortisol concentrations of both choline intake groups (range: 5.9 – 56.3 μg/dL) 
were consistent with previous observations in uncomplicated pregnancies (26). Both vaginal 
birth (P = 0.004) and primiparous pregnancy (P = 0.04) positively affected the concentration 
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Figure 1.1. Effect of maternal choline intake (930 versus 480 mg/d) on maternal and 
fetal cortisol. A) For neonates born vaginally, cord plasma cortisol tended to be lower 
(P = 0.07 controlling for parity; n = 7-8 per treatment group) in the 930 versus 480 
mg choline/d maternal intake group. B) No differences (P = 0.17; n = 10-11 per 
treatment group) were detected in maternal plasma cortisol at delivery between the 
choline intake groups. C) No correlation (Pearson’s correlation r = 0.13; P = 0.60) 
was detected between cord and maternal plasma cortisol concentrations. For A) and 
B), dashed lines represent predicted mean or mean cortisol concentrations for each 
choline intake group, respectively.  
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of cord plasma cortisol. Because the number of women giving birth through caesarean section 
was small (n = 2-3/choline intake group), only cases of vaginal birth were further analyzed. 
In this subset of samples, cord plasma cortisol concentrations tended to be 33% lower (P = 
0.07, controlling for parity) in babies born to mothers consuming 930 (20.9 ± 3.6 μg/dL, n=8) 
versus 480 (31.1 ± 3.6 μg/dL, n=7) mg choline/d (Figure 1.1A). Maternal plasma cortisol did 
not differ (P = 0.17) between the choline intake groups (930 mg/d: 46.1 ± 8.3 vs. 480 mg/d: 
61.1 ± 6.4 μg/dL) (Figure 1.1B), nor did it correlate with cord plasma cortisol (Pearson’s 
correlation r = 0.13, P = 0.60) (Figure 1.1C). As expected (26, 27), maternal plasma cortisol 
was higher (P < 0.001) than cord plasma cortisol. 
Site specific CpG methylation 
CRH and NR3C1 
We assessed CpG methylation of the proximal promoter region of CRH. This region 
interacts with several transcription factors that regulate CRH expression (Figure 1.2A) (8). 
Five CpG units in this region met our quality control criteria and were included in the final 
analyses. In placental tissue, the higher maternal choline intake (930 vs. 480 mg/d) yielded 
higher (P = 0.05, controlling for infant sex) average CpG methylation of the CRH promoter 
region (Figure 1.2B). In addition, although statistical significance was not achieved, 
methylation of each individual CpG unit was consistently higher in the 930 mg choline/d 
group (Figure 1.2C). The higher maternal choline intake also resulted in lower (P = 0.04) 
placental CRH gene transcript abundance (Figure 1.2D). In cord leukocytes, the higher 
maternal choline intake yielded lower (P = 0.05) average promoter methylation of CRH 
(Figure 1.2E) and lower (P = 0.02) methylation of CpG unit A (containing CpG site 1) 
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(Figure 1.2F). Maternal choline intake did not affect maternal blood leukocyte average CpG 
methylation of CRH (480 mg/d group: 62.4 ± 0.7%; 930 mg/d group: 61.8 ± 0.8%; P = 0.39). 
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Figure 1.2. Effect of maternal choline intake (930 versus 480 mg/d) on CRH promoter 
region CpG methylation and gene expression. A) Sequence map of the individual CpGs 
analyzed by Epityper and the binding sites of select transcription factors (8). B) Average 
placental CRH CpG methylation. C) Placental CRH CpG methylation of the individual 
CpG units. D) Placental CRH gene transcript abundance relative to the 480 mg/d group. E) 
Average cord leukocyte CRH CpG methylation. F) Cord leukocyte CRH CpG methylation 
of the individual CpG units. Gray bar, 480 mg choline/d group; black bar, 930 mg choline/d 
group. CpG units A, B, H, I, J cover CpG sites 1, 2, 8, 9, 10, respectively (Supplemental 
Table S1.2). Only CpG units that achieved a measurement success rate >75% were 
included in the analyses and were shown in C) and F). Values represent means ± SEM, 
except for B) and C) which are predicted means controlling for infant sex; n = 11-12 per 
treatment group. * P ≤ 0.05 between choline intake groups.  
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We also examined CpG methylation of the CpG-rich region of NR3C1 including exon 1F 
(Figure 1.3A). In rats, hippocampal CpG methylation of the homolog of this region (Nr3c1 
exon 17) is altered by maternal care with downstream effects on HPA axis reactivity (10). As 
rat Nr3c1 exon 17 (and presumably human NR3C1 exon 1F) contains a binding site for nerve 
growth factor inducible protein A (NGFI-A), the methylation state of this region may modify 
NGF1-A binding with subsequent effects on NR3C1 expression. In the present study, 15 CpG 
units within this region were included in the analyses. The higher maternal choline intake 
(930 versus 480 mg/d) yielded higher (P = 0.002) average placental NR3C1 promoter 
methylation (Figure 1.3B), as well as higher placental methylation of CpG unit C (containing 
CpG sites 5-7) (P = 0.01), F (containing CpG site 12) (P = 0.001), M (containing CpG site 29) 
(P = 0.003) and N (containing CpG sites 30-32) (P = 0.05) (Figure 1.3C). In cord leukocytes, 
the higher maternal choline intake yielded lower (P = 0.04) average NR3C1 promoter 
methylation (Figure 1.3D), as well as lower (P = 0.003) methylation of CpG unit E 
(containing CpG sites 10, 11) (Figure 1.3E). However, maternal choline intake did not alter 
methylation of placental or cord leukocyte CpG unit R (CpG sites 37, 38) (P = 0.55 and 0.99, 
respectively), where the predicted NGFI-A binding site resides; nor did it alter placental 
NR3C1 transcript abundance (P = 0.44). Maternal choline intake did not affect maternal 
blood leukocyte average CpG methylation of NR3C1 (480 mg/d group: 5.0 ± 0.2%; 930 mg/d 
group: 5.5 ± 0.3%; P = 0.11). 
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Figure 1.3. Effect of maternal choline intake (480 versus 930 mg/d) on NR3C1 promoter 
region CpG methylation. A) Sequence map of individual CpGs analyzed by Epityper in 
NR3C1 exon 1F (1). NR3C1 contains multiple non-translated exon 1s. Translation starts 
from exon 2. The exon 1F contains a predicted NGFI-A binding site (underlined). B) 
Average NR3C1 placental CpG methylation. C) Placental NR3C1 CpG methylation of the 
CpG units. CpG unit R represents the NGFI-A binding site. D) Average NR3C1 cord 
leukocyte CpG methylation. E) Cord leukocyte NR3C1 CpG methylation of the CpG units. 
A CpG unit may contain one or multiple CpG sites (Supplemental Table S1.2). Only CpG 
units had measurement success rates >75% were included in the analyses. Gray bar, 480 mg 
choline/d group; black bar, 930 mg choline/d group. Values represent means ± SEM; n = 8 - 
12/treatment group. ** P < 0.01 or * P ≤ 0.05 between choline intake groups.  
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GNAS-AS1, IGF2, IL10 and LEP 
To further investigate the influence of maternal choline intake on site specific DNA 
methylation, the promoter CpG methylation of 4 additional genes involved in different 
physiological pathways was assessed. For GNAS-AS1, average placental and cord blood 
leukocyte CpG methylation were not altered by maternal choline intake (P = 0.17 and 0.88 
respectively); however, CpG unit C (containing CpG site 5) of GNAS-AS1 displayed lower (P 
= 0.02) placental methylation in the 930 versus the 480 mg choline/d intake group 
(Supplemental Figure 1). The average and individual CpG methylation of IGF2, IL10 and 
LEP were not altered (P = 0.20 – 0.87) by maternal choline intake in either placental tissue or 
cord blood leukocytes (Table 1.3 and Supplemental Figure S1.1). However, our ability to 
detect subtle alterations in DNA methylation within these genes was precluded by the study’s 
small sample size.  
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Table 1.3 
Percent DNA methylation of selected genes in the placental and cord leukocyte samples obtained from the 480 and 930 mg choline /d maternal 
intake groups 
  Placenta  Cord leukocyte 
Gene Functiona  480 mg/d 930 mg/d P value  480 mg/d 930 mg/d P value 
 
GNAS-AS1 
 
Growth regulation 
  
50.5 ± 1.0 
 
48.0 ± 1.4 
 
0.17 
  
32.2 ± 1.0 
 
32.5 ± 1.0 
 
0.88 
IGF2 Growth regulation  36.5 ± 1.5 33.5 ± 1.6  0.21b  35.4 ± 0.8 36.4 ± 1.4 0.87 
IL10 Anti-inflammation  79.0 ± 0.5 77.6 ± 0.6 0.20  22.6 ± 1.2 21.1 ± 1.1 0.38 
LEP Energy metabolism  24.5 ± 1.6 23.9 ± 1.7 0.78  14.9 ± 0.7 14.0 ± 0.8  0.34c 
 
aModified from Talens et al.(17). bThe statistical analysis controlled for parity. Values presented are predicted means. cThe statistical analysis 
controlled for infant sex. Values presented are predicted means. Data without notation are presented as mean ± SEM. 
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Global DNA methylation 
Placental global DNA methylation was 22% higher (P = 0.02) in the 930 mg choline/d 
maternal intake group (4.4 ± 0.2%) compared to the 480 mg choline/d group (3.6 ± 0.2 %) 
(Figure 1.4A). Because the study participants consumed 20% of their total choline intake as 
trimethyl-d9 choline chloride (i.e., methyl groups of the choline molecule are labeled with  
deuterium) throughout the last half of the study, we were able to examine placental isotopic  
enrichment percent of 5mdC, i.e. d3-5mdC / total 5mdC * 100. Remarkably, placental 
enrichment of 5mdC was detected in both choline intake groups (480 mg/d: 0.14 ± 0.02 vs. 
930 mg/d: 0.21 ± 0.03%) and tended to be higher (P = 0.09) in the 930 mg choline/d group 
(Figure 1.4B). This finding demonstrates unequivocally that dietary choline derived methyl 
groups are used for DNA methylation and support the putative role of choline as an 
epigenetic regulator of gene expression.   
Leukocyte global DNA methylation in maternal (480 mg/d: 5.2 ± 0.3 vs. 930 mg/d: 5.0 ± 
0.2%; P = 0.50) and cord (480 mg/d: 5.0 ±0.1 vs. 930 mg/d: 4.9 ±0.1%; P = 0.60) blood was 
not altered by maternal choline intake.  
As previously reported by others (28), global DNA methylation percent was lower (P < 
0.001) in placental tissue than cord and maternal leukocytes. No correlations in global DNA 
methylation were observed among maternal leukocytes, cord leukocytes and placental tissue.  
Global histone methylation 
Placental H3K9me2, a transcription repression and heterochromatin marker, was 20% 
higher (P = 0.02) among women consuming 930 versus 480 mg choline/d (Figure 1.4C) and 
was positively correlated with placental global DNA methylation (Pearson’s correlation r = 
27 
 
0.40, P = 0.05). Maternal (P = 0.48) and cord leukocyte (P = 0.58) H3K9me2 did not differ 
between the choline intake groups, nor was placental H3K4me2 (P = 0.91), a transcription 
activation marker or H3K27me3 (P = 0.48), a transcription repression marker altered by 
maternal choline intake (Figure 1.4B).  
 
  
 
 
 
 
 
 
 
Figure 1.4. Effect of maternal choline intake (930 versus 480 mg/d) on epigenomic markers 
and methyltransferase gene transcript abundance. A) Percent global DNA methylation in 
placenta, cord leukocytes and maternal leukocytes. B) Deuterium labeled methylated cytosine 
enrichment (percent d3-5mdC to 5mdC) in placenta. C) Fold difference of placental global 
H3K9me2, H3K4me2 and H3K27me3. D) Fold difference of placental gene transcript 
abundance of DNMT1 and EHMT2. Gray bar, 480 mg choline/d group; black bar, 930mg 
choline/d group. Values represent means ± SEM; n = 12 /treatment group. * P ≤ 0.05, (*) P < 
0.1 between choline intake groups. 
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Gene expression of DNA and histone methyltransferases 
  To further clarify the mechanisms by which varied maternal choline intake may modulate 
epigenetic marks, the expression of several methyltransferases was examined. In placenta, the 
higher maternal choline intake (930 vs 480 mg/d) yielded higher (36%, P = 0.02) gene 
transcript abundance of EHMT2, the histone methyltransferase that mediates H3K9 
dimethylation (Figure 1.4D). In addition, the gene transcript abundance of DNMT1, the DNA 
methyltransferase that functions in DNA methylation maintenance, tended to be higher (33%, 
P = 0.09) in the 930 mg/d group (Figure 1.4D). The expression levels of DNA 
methyltransferases that mediate de novo DNA methylation establishment (e.g. DNMT3A and 
DNMT3B) and histone SUV39H1 which mediates H3K9 methylation, were not altered (P = 
0.45 - 0.61) by maternal choline intake (data not shown).  
Placental SAM and SAH 
SAM is the direct methyl donor for methylation reactions. SAH is formed when the methyl 
group of SAM is transferred to a methyl acceptor. Despite the changes in global DNA and 
histone methylation, placental concentrations of SAM, SAH and the SAM/SAH ratio did not 
differ (P = 0.38 - 0.97) between the maternal choline intake groups (Table 1.4). We suggest 
that these static measures may not adequately capture the enhanced flow of SAM through the 
methionine cycle (i.e, homeostatic mechanisms are engaged to prevent alterations in 
metabolite concentrations).   
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Table 1.4 
Placental S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) concentrations 
in the 930 versus 480 mg choline /d maternal intake groups 
 
Metabolite 480 mg/d 930 mg/d P value 
SAM, nmol/g 5.92 ± 0.32 5.90 ± 0.38 0.97 
SAH, nmol/g 1.82 ± 0.11 1.92 ± 0.08 0.53 
SAM/SAH 3.31 ± 0.16 3.10 ± 0.17 0.38 
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DISCUSSION 
This study provides compelling evidence that maternal choline intake during the third 
trimester of human pregnancy can modify global and site-specific epigenetic marks in fetal 
derived tissues. Alterations in fetal epigenetic marks by maternal choline intake may have 
long lasting functional effects as demonstrated in animal studies (6, 7). The modified 
epigenetic state of cortisol regulating genes in response to varied prenatal choline exposure is 
particularly noteworthy as it implies an effect of maternal choline intake on programming of 
the HPA axis.   
Maternal choline intake alters the epigenetic profile of cortisol regulating genes 
CRH is a main regulator of HPA axis reactivity and cortisol production. During pregnancy, 
large amounts of CRH are produced by placenta (expressed in high primate species only), 
which stimulate the HPA axis in both the maternal and fetal compartments to produce cortisol 
(29, 30). In the present study, promoter methylation of placental CRH was higher, and its 
transcript abundance lower, in women consuming 930 versus 480 mg choline/d. The observed 
alteration in CpG methylation may have modified the expression of CRH by changing 
accessibility of transcription factors to their regulatory elements in this region (8). The 
decrease in placental CRH expression in the higher maternal choline intake group may 
attenuate fetal HPA axis reactivity and is consistent with the ~33% lower cord plasma cortisol 
concentrations in babies of mothers consuming 930 versus 480 mg choline/d.   
NR3C1 encodes the glucocorticoid receptors and is regulated by promoter region 
methylation (1, 2, 10). In the placenta, glucocorticoids bind to glucocorticoid receptors which 
stimulate CRH expression via a feedforward mechanism (unlike the central HPA axis where 
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glucocorticoids inhibit CRH by a negative feedback mechanism) (8). The increased 
methylation of the placental glucocorticoid receptor observed in the present study may 
decrease its expression and attenuate placental expression of CRH. Nonetheless, we were 
unable to detect a change in the transcript abundance of placental NR3C1.  
The change in the epigenetic state of the cortisol regulating genes was not limited to 
placenta. However, in contrast to placenta, cord leukocyte CRH and NR3C1 methylation were 
lower in the 930 versus 480 mg choline/d intake group. The lower CpG methylation of cord 
leukocyte CRH and NR3C1 in the 930 mg/d group may represent a secondary response to the 
altered epigenetic state of the placental HPA axis genes and to the lower circulating cortisol. 
Decreased promoter methylation of NR3C1 in the central HPA axis is associated with 
increased sensitivity to cortisol stimuli and improved feedback inhibition (10). While the 
value of leukocyte NR3C1 promoter methylation as a proxy of hypothalamic NR3C1 and/or 
HPA reactivity has yet to be ascertained, a cross-sectional study reported a direct relationship 
between cord leukocyte NR3C1 CpG methylation in the NGFI-A binding site and salivary 
cortisol concentrations in babies at 3 months of age (1). 
These data collectively suggest that a higher maternal choline (i.e., 930 versus 480 mg 
choline) may lower fetal/neonatal circulating cortisol by altering the methylation state of 
cortisol regulating genes in both the placental and fetal compartments. Notably, abnormal 
increases in placental CRH are associated with obstetric complications such as preeclampsia 
and intrauterine growth restriction (IUGR) (30), and IUGR neonates exhibit elevated cord 
blood cortisol (31). Furthermore, a heightened fetal HPA reactivity as a result of early life 
exposures (e.g. prenatal glucocorticoid overexposure and maternal anxiety), has been shown 
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to enhance lifelong vulnerability to stress induced illness and chronic conditions such as 
hypertension and insulin resistance (13, 15, 16). As such, the study findings raise the exciting 
possibility that prenatal choline supplementation may be employed therapeutically in cases 
where excess maternal stress (i.e., anxiety, depression) and/or other prenatal conditions might 
adversely affect fetal HPA axis reactivity and increase vulnerability to stress-related diseases. 
Maternal choline intake affects placental global DNA and histone methylation 
The higher maternal choline intake (930 vs. 480 mg/d) yielded higher placental genome 
wide DNA methylation and H3K9me2, as well as increased expression of DNMT1 and 
EHMT2. These results are consistent with studies in rodents showing that in utero choline 
exposure altered epigenomic marks and methyltransferase expression in several fetal tissues 
(3, 5). As maintenance of DNA methylation is an important strategy to ensure genomic 
integrity and H3K9me2 is a marker of transcription repression and heterochromatin 
formation, the increase of these two epigenetic markers in placenta by a higher maternal 
choline intake may systematically affect genome stability and expression. In turn, a wide 
array of placental functions, including endocrine regulation, may be influenced by maternal 
choline intake which merits further investigation. 
Placental tissue is highly susceptible to epigenetic modification  
The role of the placenta as a mediator of fetal programming is increasingly recognized 
(11, 32). More specifically, the placenta acts on behalf of the fetus as both a sensory and 
effector organ to facilitate the incorporation of environmental information (i.e, nutrient 
exposure) into the developmental process (33). In the present study, the epigenetic state of the 
placenta was highly sensitive to varied maternal choline intake during the third trimester of 
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pregnancy with nearly all the examined placental epigenetic marks (global and site specific 
DNA methylation, global histone methylation) showing some degree of alteration. On the 
contrary, the leukocyte epigenetic state of the mothers, who received the choline treatment 
directly, was relatively stable. The plasticity of the placental epigenome in response to 
maternal nutrition may provide a mechanism through which the maternal environment can 
alter placental function and ultimately fetal development.  
 
 
Figure 1.5. A proposed mechanism by which a higher maternal choline intake may modulate 
the epigenetic and epigenomic marks of fetal derived tissues. Solid arrows, process enhanced 
by a higher maternal choline intake; dashed arrows: process attenuated by a higher maternal 
choline intake.  
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Proposed mechanism by which maternal choline intake modulates epigenetic and epigenomic 
marks 
Maternal choline intake may alter the epigenetic and epigenomic marks of fetal derived 
tissues by influencing the supply of methyl donors (Figure 1.5). The use of choline as a 
methyl donor transpires predominately in the liver where the choline derivative, betaine, 
provides a methyl group for the conversion of homocysteine to methionine in a reaction 
catalyzed by betaine-homocysteine S-methyltransferase (BHMT) (34). Following the 
activation of methionine to SAM, the choline-derived methyl group may be used in cellular 
methylation reactions including the methylation of DNA and histones. As the placenta does 
not express BHMT, the choline-mediated placental epigenetic and epigenomic modifications 
that were observed in the present study, depend on the maternal supply, and placental uptake, 
of methionine and SAM, both of which can transport choline/betaine derived methyl groups 
from the maternal liver to extrahepatic tissues including the placenta and fetus.  
As shown in Figure 1.5, we propose that the higher maternal choline intake increased the 
use of choline as a methyl donor for methionine and SAM production in the maternal 
compartment. Uptake of methionine and SAM by the placental tissue yielded greater 
placental global DNA methylation and H3K9me2, as well as greater CRH promoter CpG 
methylation, either directly (increased placental uptake and utilization of methionine and 
SAM) and/or indirectly via upregulation of DNMT1 and/or EHMT2. A higher CRH 
methylation diminished CRH transcription and the entry of CRH into the fetal compartment. 
In turn, stimulation of the fetal central HPA axis and adrenal production of cortisol was 
attenuated thereby lowering circulating concentrations of cortisol. This reduction in 
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circulating fetal cortisol concentrations may have triggered other regulatory events that 
resulted in a lowering of CRH and NR3C1 CpG methylation.  
Conclusions 
 In summary, the study findings suggest that maternal choline intake throughout the third 
trimester of pregnancy can alter placental epigenomic marks as well as the epigenetic state of 
key modulators of placental and fetal HPA axis reactivity. As such, the study findings raise 
the exciting possibility that a higher maternal choline intake may counter some of the adverse 
effects of prenatal stress on behavioral, neuroendocrine and metabolic development in the 
offspring. The investigation of the influence of genetic variants in one-carbon metabolizing 
genes on epigenetic and epigenomic responses to varied maternal choline intake are planned. 
Additional studies in larger independent cohorts are needed to replicate these results and 
explore the long-term functional consequences of these choline-induced epigenetic 
alterations. 
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Supplemental Table S1.1. Information of the gene promoter regions where CpG methylation was measured and primers used 
 
aPrimers were previously published by Talens et al (17) and Oberlander et al (1). The 5’ ends of the forward primers are connected with a 
10-mer tag: 5’ AGGAAGAGAG + forward primer 3’; the 5’ ends of the reverse primers are connected with a T7 tag: 5’ 
CAGTAATACGACTCACTATAGGGAGAAGGCT + reverse primer 3’. †This pair of primers was used for placental and cord leukocyte 
samples. Primers for maternal leukocytes were F: 5’ GATTTGGTTTTTTTGGGG 3’; R: 5’ TCCCTTCCCTAAAACCT 3.  
Gene symbol Chromosome Length No. of CpG sites Forward primer
a Reverse primer 
CRH chr8:67,090,692 -67,091,132 441bp 10 5'TGGTTGTTGTTTTTTTGGTAGG 3' 5'CTCCACTCCAAAACCTAAAATAAA 3' 
GNAS-AS1 chr20:57,425,81 -57,426,119 305bp 19 5'GTAATTTGTGGTATGAGGAAGAGTGA 3' 5'TAAATAACCCAACTAAATCCCAACA 3' 
IGF2 chr11:2,169,459 -2,169,796 338bp 8 5'TGGATAGGAGATTGAGGAGAAA 3' 5'AAACCCCAACAAAAACCACT 3' 
IL10 chr1:206,946,011 -206,946,339 329bp 4 5'TGATTGGTTGAATATGAATTTTTGTAT 3' 5'CACCCCCTCATTTTTACTTAAAAA 3' 
LEP chr7:127,881,054 -127,881,410 357bp 32 5’GTTTTTGGAGGGATATTAAGGATTT 3’ 5’CTACCAAAAAAAACCAACAAAAAAA 3’ 
NR3C1 chr5:142,783,501 -142,783,908 408bp 47 5’TTTTTTTGAAGTTTTTTTAGAGGG 3’ 5’ CCCCCAACTCCCCAAAA 3’ 
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Supplemental Table S1.2. The corresponding CpG sites of each CpG unit 
 
CpG unit Corresponding CpG sites 
CRH GNAS-AS1 IGF2 IL10 LEP NR3C1a NR3C1b
A 1 1,2 1 1 1 1 1~2 
B 2 3,4 2 2,3 2~7 2~4 3 
C 3 5 3 4 8 5~7 4 
D 4 6 4 9,10 8,9 5~6 
E 5 7 5 11 10,11 7~8 
F 6 8,9 6,7 12,13 12 9 
G 7 10~12 8 14,15 13 10~11 
H 8 13,14 16,17 14 12~13 
I 9 15 18 15~21 14 
J 10 16 19-21 22 15~16 
K 17-19 22 23,24 17~20 
L 23,24 25~28 21 
M 25 29 22~28 
N 26 30~32 29 
O 27 33 30 
P 28 34 31 
Q 29 35,36 32 
R 30~32 37,38 33~34 
S 39 35~41 
T 40 42 
U 41,42  
V 43~47  
aFor placental and cord leukocyte samples; bfor maternal leukocyte samples 
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Supplemental Table S1.3. Selection of CpG units for final analyses  
Gene 
symbol  
CpG units included  CpG units excludeda  
CRH A, B, H~J C, D (SN); E (H_mass); F, G (D) 
GNAS-AS1 A~K 
IGF2 A-D, F, G E (NS) 
IL10 A~C 
LEP A, C~N, P, Q B, R (H_mass); O (NS) 
NR3C1b A-G, K, M, N, P~R, T, U H, J, O, S (L_mass); I, L, V(H_mass)
NR3C1c E, F, H~J, L, N~P, R, T 
A, G, K, M, S (H_mass); B, Q 
(L_mass); C, D (NS) 
aCpG units were included if 75% samples had successful measurements; Reasons for 
exclusion were indicated in parentheses. NS: not specified; SN: high signal to noise ratio; 
H_mass: the CpG unit had high mass and was not reliably detected; L_mass: the CpG unit 
had low mass and was not reliably detected; D: duplicate CpG unit (e.g. two CpG units being 
of the same mass). bFor placental and cord leukocyte samples. cFor maternal leukocyte 
samples. 
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Supplemental Figure S1.1. Effects of maternal choline intake (930 versus 480 mg choline /d) 
on the placental (A-D) and cord leukocyte (E-H) CpG methylation of the individual CpG 
units of GNAS-AS1, IGF2, LEP and IL10. Gray bar: 480 mg choline /d group; black bar: 930 
mg choline /d group. Values represent means ± SEM, except for (B) and (G), which are 
predicted means controlling for parity and infant sex, respectively; n = 11-12 per treatment 
group. * P ≤ 0.05 between choline intake groups. 
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CHAPTER 2 
A higher maternal choline intake among third trimester pregnant women lowers 
placental and circulating concentrations of the anti-angiogenic factor fms-like tyrosine 
kinase-1 (sFLT1)* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Jiang X, Bar HY, Yan J, Jones S, Brannon PM, West AA, Perry CA, Ganti A, Pressman E, 
Devapatla S, Vermeylen F, Wells MT, Caudill MA. A higher maternal choline intake among 
third-trimester pregnant women lowers placental and circulating concentrations of the 
antiangiogenic factor fms-like tyrosine kinase-1 (sFLT1). FASEB J. 2012 Nov 29. [Epub 
ahead of print] 
Copyright approval has been obtained from The FASEB Journal (Appendix B). 
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ABSTRACT 
This study investigated the influence of maternal choline intake on the human placental 
transcriptome, with a special interest in its role in modulating placental vascular function. 
Healthy pregnant women (n=26, wk 26-29 gestation) were randomized to 480 mg choline/d, 
an intake level approximating the adequate intake of 450 mg/d, or 930 mg/day for 12-wk. 
Maternal blood and placental samples were retrieved at delivery. Whole genome expression 
microarrays were conducted in a subset of samples (n=6 / maternal choline intake group) to 
identify placental genes and biological processes impacted by maternal choline intake. 
Maternal choline intake influenced a wide-array of genes (n=166) and biological processes 
(n=197) including those related to vascular function. Of special interest is the anti-angiogenic 
factor and preeclampsia risk marker fms-like tyrosine kinase-1 (sFLT1). Quantitative real 
time PCR conducted in all placental samples confirmed the 30% downregulation (P=0.05) of 
sFLT1 in the placenta tissues obtained from the 930 versus 480 mg choline/d intake group. 
Similar decreases (P=0.04) were detected in maternal blood sFLT1 protein concentrations. 
The downregulation of sFLT1 by choline treatment was confirmed in a human trophoblast 
cell culture model and may be related to enhanced acetylcholine signaling. These findings 
indicate that supplementing the maternal diet with extra choline may improve placental 
angiogenesis and mitigate some of the pathological antecedents of preeclampsia. 
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INTRODUCTION 
The human placenta is a highly vascularized organ that plays a critical role in nutrient 
transport, endocrine homeostasis and immune function. Vasculogenesis and subsequent 
angiogenesis are required for proper placental development and function and are regulated by 
angiogenic factors produced by placental cells (e.g., trophoblasts) (1).   
Excess placental production of the anti-angiogenic factors, soluble fms-related tyrosine 
kinase-1 (sFLT1) and soluble endoglin, play a key role in the pathogenesis of preeclampsia (2, 
3) and possibly other diseases of pregnancy (1). These placental anti-angiogenic factors are 
released into the maternal circulation where they can sequester pro-angiogenic factors 
[vascular endothelial growth factor (VEGF), placental growth factor (PGF), and/or 
transforming growth factor beta], thereby inhibiting normal maternal endothelial cell 
signaling (2). Disturbances in maternal endothelial cell signaling cause endothelial cell 
dysfunction and result in hypertension, proteinuria, and other systemic manifestations of 
preeclampsia. Thus treatments that restore placental angiogenic balance may reduce the risk 
of diseases caused by placental dysfunction (2, 4, 5).  
 Choline is an essential nutrient that functions in phospholipid metabolism, 
neurotransmission, and as a methyl donor (6). Several biological processes are modified by 
choline supply including inflammation (7), apoptosis (8), and angiogenesis (9). During 
pregnancy, the demand for choline increases substantially to support the growth and 
development of the placenta and fetus (6, 10-12). Notably, supplementing the maternal rodent 
diet with extra choline during pregnancy yields lasting improvements in offspring cognitive 
functioning (13) and reduces vulnerability to mammary tumors in the female offspring (14). 
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The lasting beneficial effects of maternal choline intake on offspring cognitive and 
physiologic functioning are mediated in part by epigenetic mechanisms, e.g. altering DNA 
and histone methylation (15). Notably, the epigenome of the human placenta is especially 
responsive to maternal choline intake. Specifically, we showed that a higher maternal choline 
intake (930 versus 480 mg/d) yielded 22% higher placental genome-wide methylation and 
altered the methylation state, and expression, of placental corticotropin-releasing hormone 
(16). In addition, we observed an elevation in placental acetylcholine, which plays a critical 
role in placenta development and function, in the 930 versus 480 mg/d choline intake group 
(11). These data collectively indicate that maternal choline intake may alter several biological 
processes in the placenta including its vascular development.  
 As an extension of our previous work (11), this study investigated the effects of maternal 
choline intake on the placental transcriptome, with a special interest in its role in modulating 
placental vascular function. To achieve these aims, we conducted whole genome expression 
microarrays on placental tissues previously obtained from third trimester pregnant women 
randomized to either 480 mg choline/d, an intake level slightly above the adequate intake of 
450 mg/d, or 930 mg/day for 12-weeks (11). Biological processes of particular interest, such 
as angiogenesis, were further investigated with a human placental cell culture model.  
  
49 
 
MATERIALS AND METHODS 
Study participants 
Healthy third trimester (weeks 26-29 gestation) singleton pregnant women aged ≥ 21y 
were recruited from Ithaca, New York, and surrounding areas between January 2009 and 
October 2010. Entry into the study was contingent upon good health status as assessed by a 
blood chemistry profile, complete blood count and medical history questionnaire. Additional 
inclusion criteria included no tobacco or alcohol use, no history of chronic disease, normal 
kidney and liver function, and a willingness to comply with the study protocol (11). Exclusion 
criteria included the use of prescription medications known to affect liver function, multiple 
pregnancy, or pregnancy associated complications, e.g., preeclampsia, gestational diabetes.   
The screening and experimental procedures were approved by the Institutional Review 
Boards for Human Participants at Cornell University and Cayuga Medical Center, and written 
informed consent was obtained prior to study entry. The study was registered at 
ClinicalTrials.gov as NCT01127022 (http://clinicaltrails.gov/) and the CONSORT flowchart 
has been reported (11). 
Study design, diet and supplements 
This was a 12-wk controlled feeding study in which pregnant women (n = 26) were 
randomized to either 480 (approximating the adequate intake level; n=13) or 930 (n=13) mg 
choline/d as previously described (11). The choline was derived from the diet (380 mg/d) plus 
supplemental choline chloride (either 100 or 550mg choline/d for the 480 or 930 mg/d intake 
levels, respectively). Throughout the 12-wk study, the participants consumed a 7-day cycle 
menu (11). All food and beverage was provided by the investigators and one meal per day 
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was consumed on-site throughout the week. All other meals and beverages were provided as 
take-away.  
In addition to the supplemental choline (Balchem, New Hampton, NY, USA), study 
participants consumed a daily 200 mg docosahexaenoic acid supplement (Neuromins, 
Nature’s Way Products, Springville, UT, USA), a daily over-the-counter prenatal 
multivitamin supplement (Pregnancy Plus®, Fairhaven Health, LLC, Bellingham, WA, USA), 
and a thrice weekly potassium/magnesium supplement (General Nutrition Corp., Pittsburgh, 
PA, USA) in order to achieve recommended nutrient intake levels not met with the study diet. 
When eating on-site, participants consumed supplements under the supervision of study 
personnel. Otherwise, supplements were provided in plastic bags along with take-away meals 
and participants were instructed to consume the supplements with a meal of their choice. At 
the end of the study, participants continued on their choline supplement until the delivery of 
their babies (11). The study design, diet composition and supplements, and participant 
compliance were fully described in Yan et al, 2012 (11). 
At delivery, placental and maternal blood samples were retrieved from 24 of the 26 
participants (n = 12/ choline intake group). Information regarding the health status of the 
study participants, the delivery, and the health parameters of the newborns were obtained 
from medical charts. 
Sample collection 
Fasting (10-h) venous serum samples were obtained at study baseline (week 0) and within 
24 hours before delivery at the hospital in a 10mL serum separator gel and clot-activator tube 
(SST Vacutainer; Becton, Dickinson and Company, Franklin Lakes, NJ, USA) (11). Placental 
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samples were processed at the hospital within 90 minutes of delivery (16). After removal of 
the amnion, the placenta was visually divided into four quadrants and full thickness biopsies 
were taken from each quadrant. The biopsies were immediately rinsed with phosphate 
buffered saline and stored in tubes with RNAlater® (Qiagen, Valencia, CA, USA) which was 
added to prevent RNA degradation. All samples were stored at -80°C. As the placenta is a 
heterogeneous tissue, the results obtained from the study represent an average effect of 
maternal choline intake on a subset of placental cells. The difference in the placental 
biomarkers observed in the two maternal choline intake groups could be attributed to the 
differential production of these biomarkers in a specific cell type, changes in placental cell 
population composition, and/or changes in cell numbers. 
HTR-8/SVneo cell culture 
   HTR-8/SVneo is a stable cell line derived from human first trimester placental 
extravillous trophoblast and immortalized with the large T-antigen SV-40 (17). The cells, 
kindly provided by Dr. Charles Graham (Queens University, Kingston, Ontario, Canada), 
were maintained in RPMI1640 culture medium (Mediatech. Inc, Manassas, VA, USA) with 
2mM L-glutamine and 5% fetal bovine serum (FBS) in 5% CO2-95% air at 37⁰C. For 
experiments, customized RPMI1640 medium (Life Technologies, Grand Island, NY, USA) 
which contained no choline, 2mM L-glutamine and 1.25% FBS were used. The FBS provided 
the cells with 8 μM total choline (including free choline, phosphocholine, 
lysophosphatidylcholine, glycerophosphocholine, phosphatidylcholine and sphingomyelin) as 
measured by liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) in 
our laboratory (11). Choline chloride was added to the media in the amounts of 0, 5 and 20 
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μM, yielding total choline concentrations of 8, 13 and 28 μM, and generating a low, medium 
and high choline group, respectively. Cells were seeded in the media containing the different 
choline concentrations at a starting amount of 1.39×106 cells (passages 5-20) per 100×20 mm 
dish (BD Biosciences). The cells were cultured for 96-h before harvest. Cell counts were 
performed with a TC10™ automatic cell counter (Bio-Rad, Hercules, CA, USA). Cell 
viability was measured by Trypan blue dye exclusion. RNA and protein were extracted as 
described below.  
RNA extraction 
  Total RNA was extracted from the placental tissue and HTR-8/SVneo cell samples via 
commercially available kits [RNeasy Mini kit (Qiagen) for the placental tissue and 
PerfectPure RNA cultured cell kit (5 Prime Inc, Gaithersburg, MD, USA) for the cells]. The 
integrity of the RNA samples prepared for the microarray was determined using an Agilent 
2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Only samples with an RNA 
Integrity Number >8.0 (n = 6 per choline intake group) were used for the microarray analysis. 
Agarose gel electrophoresis was used to ensure intact ribosomal bands in the trophoblast 
RNA. 
Microarray preparation and data analysis 
Microarrays were conducted in samples (n = 6/ maternal choline intake group) that met 
the RNA integrity cut off noted above. Antisense RNA amplification and cyanine-3 labeling 
were performed with an Amino Allyl MessageAmp II aRNA amplification kit (Ambion Inc., 
Grand Island, NY, USA). Microarray hybridization was performed at 65ºC for 17-h in an 
Agilent Microarray Hybridization oven. Microarray scanning was performed in an Agilent 
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Scanner (G2505C) and the images were extracted using Agilent Feature Extraction Software 
10.5. Data normalization was performed using log2 transformation and median normalization. 
An extension of the Laplace approximation EM Microarray Analysis (LEMMA) package 
based on the R software platform (18) developed by Bar et al. (19, 20) was used to detect 
differentially expressed genes. The version used here (Bar H.Y., unpublished observations) 
can sensitively detect differentially expressed genes, as it takes into account not only mean 
differences, but also variational differences between the two treatment groups. The 
differentially expressed genes were declared by controlling the false discovery rate (FDR) of 
< 0.2 and an expression fold difference of > 1.5. Differentially expressed genes were 
classified according to their gene ontology using High-Throughput GoMiner (21). All data is 
compliant with the Minimum Information About a Microarray Experiment (MIAME) 
guideline. The data have been deposited in the NCBI's Gene Expression Omnibus database 
(22) as detailed on MGED Society website 
(http://www.mged.org/Workgroups/MIAME/miame.html), and are accessible through GEO 
Series accession number GSE39290. Microarray results of select genes were verified using 
quantitative real-time PCR.  
Reverse transcription and quantitative real-time PCR 
Reverse transcription and quantitative real-time PCR were performed in all placental 
samples (n = 12 / maternal choline intake group) as previously described (23). All primers 
were designed using GeneRunner Version 3.01 (http://www.softpedia.com/). The primers for 
FLT1 transcripts [sFLT1, membrane bound FLT1 (mFLT1) and total FLT1], the choline 
metabolizing genes [i.e., phosphate cytidylyltransferase 1, choline, alpha (PCYT1A), 
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phosphatidylethanolamine N-methyltransferase (PEMT), choline dehydrogenase (CHDH)], 
the cholinergic receptor, muscarinic 4 (CHRM4), and the housekeeping genes [i.e., 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and beta glucuronidase (GUSB)] are:  
CHDH, F: 5'-GCAAGGAGGTGATTCTGAGTGG-3'; 
R:5'-GGATGCCCAGTTTCTTGAGGTC-3' 
CHRM4, F: 5’-TGTGCTGATCTCATCATAGGC-3';  
R:5’-TCACCACGTAGTCCAGGGC-3' 
mFLT1, F: 5'-AGGGGAAGAAATCCTCCAGAAG-3';  
R: 5'-GCATGACAGTCTAAAGTGGTGG-3' 
sFLT1, F: 5'-AGGGGAAGAAATCCTCCAGAAG-3';  
R: 5'-GTGGTACAATCATTCCTTGTGCT-3' 
total FLT1, F: 5’- CACATGACTGAAGGAAGGGAGC-3’;  
R: 5’-GTCCCAGATTATGCGTTTTCCA-3’ 
GAPDH, F: 5'-TGTTGCCATCAATGACCCCTT-3';  
R: 5'-CTCCACGACGTACTCAGCG-3' 
GUSB, F: 5'-CTCTTGGTATCACGACTACGGG 3';  
R: 5'-CAATCGTTTCTGCTCCATACTC-3' 
PCYT1A, F: 5'-CAGAAGGTGGAGGAAAAAAGCA-3';  
R: 5'-TATGTTTCAGTGCTCCTTCCGG-3' 
PEMT, F: 5'-GGGGTTCGCTGGAACTTTC-3';  
R: 5'-GCCCAGGTAGTTGGCTGTG-3' 
Data were expressed by the delta delta Ct method in which the expression level of the gene of 
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interest was normalized by the expression level of housekeeping gene as fold change before 
comparison between samples (24). GAPDH and GUSB were used as the housekeeping gene 
for the placental tissue or the cell culture model, respectively.  
sFLT1 measurement 
Circulating concentrations of sFLT1 in maternal serum samples obtained at study baseline 
and at delivery were measured using an ELISA kit (R&D systems, Minneapolis, MN, USA) 
according to the manufacturer’s instructions.  
FLT1 promoter cytosine-phosphate-guanine (CpG) methylation 
Site specific promoter methylation of FLT1was analyzed using base-specific cleavage and 
mass spectrometry (25). Briefly, genomic DNA was extracted via the DNeasy blood & tissue 
kit (Qiagen) and bisulfite-treated using the EZ DNA methylation kit (Zymo, Irvine, CA, 
USA). The FLT1 promoter region was PCR amplified using the bisulfite-treated DNA as the 
template and published primers (26). The T7 tag and 10 mer tag were incorporated into the 
reverse and forward primers respectively. The primers were: 
Forward: 5’ aggaagagagGGTGGAGGGAGTTTGTAAGGA 3’ 
Reverse: 5’ cagtaatacgactcactatagggagaaggct CCTCCCCACCTACCCTCTTC 3’  
 The amplification products were analyzed with the MassArray EpiTYPER system 
(Sequenom Inc, San Diego, CA, USA) at the Cornell Life Sciences Core Laboratories Center 
(Cornell University). Percent methylation of the cytosine residues was determined for each 
CpG unit, which may contain one or multiple adjacent CpG dinucleotides (CpG sites) that 
cannot be resolved individually by EpiTYPER. Only CpG units with measurement success 
rates of > 75% were included in the final analyses (27).  
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Cellular sFLT1 protein measurements 
  sFLT1 protein concentrations in the HTR-8/SVneo cells were measured with western blot 
assays. The protein was extracted with PhosphoSafeTM Extraction Reagent and protease 
inhibitor cocktail set III (EMD Millipore, Billerica, MA, USA), subjected to SDS-PAGE 
electrophoresis and transferred to polyvinylidene fluoride membrane. Rabbit anti-human 
sFLT1 primary antibody (Life Technologies) and reference protein primary antibody (mouse 
anti-human β-actin, Cell Signaling Technology, Danvers, MA, USA) were added overnight at 
4oC, after which secondary antibodies, IRDye 800CW Goat Anti Rabbit and IRDye 680 Goat 
Anti mouse (LI-COR, Lincoln, NE, USA), were added. Target protein bands were visualized 
and quantified by the LI-COR Odyssey® imaging system (LI-COR) and expressed as the 
ratio of intensity of sFLT1 to the reference protein (β-actin).  
Statistical analysis 
  Student’s t-tests (for continuous dependent variables) and Chi-square tests (for categorical 
variables) were performed to test for difference in the dependent variables between the 
choline intake groups at study baseline and at delivery. General linear models (GLMs) were 
used to assess the effect of maternal choline intake on the dependent variables (e.g. placental 
mRNA abundance, circulating sFLT1). Candidates for entry as covariates into the GLMs are 
listed in Table 2.1. All 2-way interactions between the covariates and maternal choline intake 
were tested in the models. The covariates and interactions not achieving a statistical 
significance of P < 0.05 were removed from the models in a stepwise process. Covariates 
retained in the final statistical models are specified following the presentation of the P values.  
 One-way ANOVA followed by post-hoc Fisher’s LSD tests were performed to assess the 
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effects of choline treatment on cell count and sFLT1 expression in the cell culture model. The 
maternal circulating sFLT1 and quantitative PCR data were log-transformed to meet the 
normality criteria (i.e. residuals were normally distributed). All analyses were performed 
using SPSS (release 18.0 for Windows, SPSS Inc, Chicago, IL). Differences were considered 
to be significant at P ≤ 0.05; P < 0.10 was considered to be indicative of trends. Values are 
presented as means +/- standard error (SE). P-values are two-tailed. 
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Table 2.1. Baseline characteristics of the third trimester pregnant women randomized to 930 
or 480 mg choline/d and the neonatal outcomes of their children ab 
Characteristics 930 mg/d, n = 12 480 mg/d, n = 12 
Maternal baseline characteristics 
Age, y (range) 28 (22-34) 29 (25-33) 
Pre-pregnancy BMI, kg/m2 (range) 23.4 (19.9-29.8) 23.6 (20.2-31.9) 
Parity, primiparas/multiparas 3/9 8/4* 
Ethnicity, Caucasian/African American/  
Latino/ Asian/Other 
6/1/2/3/0 8/0/2/1/1 
Education, high school/college 3/9 1/11 
Work status, not employed/employed 2/10 2/10 
Serum sFLT1, pg/mL 3275 ± 439 2928 ± 494 
Delivery and neonatal characteristics 
Mode of delivery, caesarean section/ vaginal 2/10 3/9 
Gestational age at birth, wk (range) 40 (39-40) 40 (39-42) 
Infant sex, female/male 4/8 3/9 
Infant birth weight, kg 3.4 ± 0.1 3.4 ± 0.1 
Infant Apgar score 8-9; 9 8-9; 9 
aData are presented as mean ± SE or (range) 
bData were analyzed with student’s t tests for continuous data and Chi-square tests for 
categorical data; *P < 0.05 between choline intake group. 
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RESULTS 
Maternal and neonatal characteristics 
Twenty-four women were included in the final analyses (n = 12 for each choline intake 
group). Baseline characteristics of these third trimester pregnant women did not differ (P > 
0.14) between the choline intake groups (i.e., 930 versus 480 mg/d) with the exception of 
parity (i.e., there were more primiparous women in the 480 mg choline/d intake group; P = 
0.04) (Table 2.1) (16). Mode of delivery, gestational age at birth, infant sex, infant birth 
weight, and Apgar score did not differ (P > 0.11) between the choline intake groups (Table 
2.1) (16). No complications (e.g., hypertension, gestational diabetes, preeclampsia) were 
observed during pregnancy, and all babies were delivered at term and were apparently 
healthy.   
Placental genes and biological processes modified by maternal choline intake  
The whole genome expression microarrays were conducted in a subset of placental 
samples (n=6/ maternal choline intake group), which suggested that 43 placental genes were 
upregulated and 123 genes were downregulated in the 930 versus 480 mg choline/d intake 
group (Supplemental Figure S2.1). Similarly, the gene ontology (GO) analysis suggested that 
197 biological processes in the placenta were altered (P < 0.05) by a higher maternal choline 
intake (930 vs 480 mg/d) (Supplemental Table S2.1).   
 Of particular interest to our research group was the differential expression of genes 
related to circulatory system development (GO: 0072359) and blood circulation (GO: 
0008015) between the two choline intake groups (Table 2.2). The majority of these 
differentially expressed genes were downregulated by the higher choline intake (930 vs. 480 
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mg/d) including FLT1, the VEGF receptor. FLT1 mediates normal endothelial signaling (26). 
However, the soluble form of this receptor (sFLT1), a splice variant lacking the 
transmembrane and cytoplasmic domains, acts as a potent VEGF and PGF antagonist and is 
elevated in women with preeclampsia (3, 28, 29). 
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Table 2.2. Differentially expressed placental vascular function genes in the 930 versus 480 mg choline/d maternal intake group identified by 
microarraya 
Gene symbol Gene name Gene function Fold differenceb 
RBP4 Retinol binding protein 4, plasma Circulatory system development 0.12  
ADORA3 Adenosine A3 receptor Vascular permeability regulation 0.32  
OXTR Oxytocin receptor Vascular tone regulation 0.38  
COL8A1 Collagen, type VIII, alpha 1 Extracellular matrice, vascular remodeling 0.41  
ERRFI1 ERBB receptor feedback inhibitor 1 Circulatory system development 0.48  
FLT1 Fms-related tyrosine kinase 1 VEGF receptor 0.49  
MYH7 Myosin, heavy chain 7, cardiac muscle, beta Circulatory system development; Blood circulation 0.52  
PTK2B PTK2B protein tyrosine kinase 2 beta Endothelial sprouting 0.53  
GHRL Ghrelin/obestatin prepropeptide Angiogenesis 1.61  
NPY5R Neuropeptide Y receptor Y5 Vascular smooth muscle cell proliferation 1.70  
ELN Elastin Arterial morphogenesis 2.03  
aThe data were derived from the genome wide microarray and were analyzed with the LEMMA statistical package.  
bFold difference is the average mRNA abundance in the 930 mg/d maternal choline intake group divided by the average mRNA abundance in the 480 
mg/d maternal choline intake group in the microarrays. 
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Placental expression and maternal circulating concentrations of sFLT1 
 To explore the possible effects of maternal choline intake on placental sFLT1 expression, 
we measured the placental abundance of the sFLT1 transcript as well as maternal circulating 
sFLT1 protein concentrations at delivery in all placental samples (n=12/ maternal choline 
intake group). Maternal serum sFLT1 concentrations ranged from 2745-18555 pg/mL which 
is similar to the concentrations reported by Reddy et al. (i.e., 1600-16,200 pg/mL) among 
normal pregnancies (30). We found lower placental sFLT1 mRNA abundance (P = 0.05, 
controlled for baseline circulating sFLT1) and lower circulating sFLT1 concentrations at 
delivery (P = 0.04, controlled for baseline circulating sFLT1) (Figure 2.1A and B) in the 930 
versus 480 mg choline/d intake group. In addition, we observed a strong positive correlation 
(r=0.70; P<0.001) between placental sFLT1 mRNA abundance and maternal circulating 
sFLT1 (Figure 2.1C) suggesting that the lower placental expression of sFLT1 contributed to 
the lower circulating concentrations of sFLT1 in maternal blood.  
As the results from a previous study (31) suggested that parity may influence sFLT1 
concentrations, we stratified the data by parity. However, as there were only 2 circulating 
sFLT1 samples available from primiparous women in the 930 mg/d group, statistical analysis 
was performed among the multiparous women only. Consistent with the analyses of the entire 
dataset, placental sFLT1 expression (P = 0.08, controlled for baseline circulating sFLT1) 
(Figure 2.1D) and maternal circulating sFLT1 (P = 0.07, controlled for baseline circulating 
sFLT1) (Figure 2.1E) tended to be lower among the multiparous women in the 930 versus the 
480 mg choline/d intake group.  
We also measured the placental transcript abundance of total FLT1 and the membrane bound 
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functional FLT1 (mFLT1). Total FLT1 tended to be lower (fold change = 0.73; P = 0.08) in 
the 930 versus 480 mg choline/d group, but mFLT1 expression did not differ (fold change = 
0.94; P = 0.49) between the 930 versus 480 mg choline/d group. The responsiveness of 
sFLT1 transcript abundance, but not mFLT1, to extra choline implies a selective effect of 
maternal choline intake on sFLT1 expression. 
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Figure 2.1. Placental sFLT1 mRNA abundance and maternal circulating sFLT1 
concentrations in the 480 and 930 mg choline/d maternal intake groups at delivery. A) 
placental sFLT1 mRNA abundance; B) maternal serum sFLT1 concentrations (pg/mL); C) 
relationship between placental sFLT1 mRNA abundance and maternal serum sFLT1 
concentrations; D) placental sFLT1 mRNA abundance among multiparous women; and E) 
maternal serum sFLT1 concentrations among multiparous women. White bar: 480 mg 
choline/d intake group. Black bar: 930 mg choline/d intake group. Values are mean ± SE, 
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The relationship between sFLT1 and other biomarkers of choline metabolism 
 To investigate the mechanism by which choline may be modulating placental sFLT1 
expression, we examined the correlations of placental and maternal circulating sFLT1 with 
the placental concentrations of several choline metabolites [e.g. choline, betaine, 
acetylcholine, published previously by Yan et al. 2012 (11)] and the placental mRNA 
abundance of several choline metabolizing genes (e.g. PCYT1A, PEMT, CHDH CHRM4). We 
found that placental sFLT1 mRNA abundance (r = -0.42, P = 0.05) and maternal circulating 
sFLT1 concentrations (r = -0.38, P = 0.08) correlated negatively with placental acetylcholine 
concentrations (Figure 2.2A and B, respectively). Similarly, placental sFLT1 mRNA 
abundance (r = -0.46, P = 0.02) and maternal circulating sFLT1 concentrations (r = -0.38, P = 
0.08) correlated negatively with placental mRNA abundance of CHRM4, a receptor for 
acetylcholine signaling (Figure 2.2C and D, respectively). In addition, CHRM4 expression 
tended to be higher (Fold difference = 1.5, P = 0.06) in the 930 versus the 480 mg choline/d 
maternal intake group which is consistent with more active signaling through the 
acetylcholine pathway in the higher maternal choline intake group.  
Effect of maternal choline on FLT1 promoter methylation 
Secondary to choline’s role as a methyl donor and the presence of CpG dinucleotides 
within the proximal promoter region of FLT1 (26), we examined the CpG methylation status 
of this region. No differences in CpG methylation were detected between the two choline 
intake groups (480 mg/d: 5.6 ± 0.4% vs. 930 mg/d: 5.0 ± 0.4%, P = 0.29) (Supplemental 
Figure S2.2).  
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Figure 2.2. Association of placental sFLT1 mRNA abundance and maternal circulating 
sFLT1 concentrations with placental acetylcholine concentrations and CHRM4 mRNA 
abundance. A) placental sFLT1 mRNA abundance (Pearson’s correlation r= -0.42, P=0.05) 
and B) maternal circulating sFLT1 concentrations (Pearson’s correlation r = -0.38, P = 0.08) 
were negatively associated with placental acetylcholine concentrations. C) placental sFLT1 
mRNA abundance (Pearson’s correlation r = -0.46, P = 0.02) and D) maternal circulating 
sFLT1 concentrations (Pearson’s correlation r = -0.38, P = 0.08) were negatively associated 
with placental CHRM4 mRNA abundance. n = 22 (including both the 480 and 930 mg 
choline/d intake groups). The data of mRNA abundance were log-transformed. Data were 
analyzed with Pearson’s correlation. 
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The effect of choline treatment on sFLT1 expression in the HTR-8/SVneo cell model 
   The immortalized placental trophoblast cell line HTR-8/SVneo was utilized to verify the 
human data of downregulation of sFLT1 expression by extra choline. The cells cultured in 
low choline concentrations (8 μM) had significantly lower (P < 0.001, 30%) viable cell 
counts than the cells cultured in the medium (13 μM) and high (28 μM) choline 
concentrations; the cells in the medium and higher groups did not differ in cell counts 
(Figure 2.3A). Consistent with the human study, the higher choline concentrations in the cell 
culture media yielded a dose response decrease (P < 0.001) in sFLT1 mRNA abundance 
(Figure 2.3B) and sFLT1 secretion to the cell culture medium (Figure 2.3C). Intracellular 
sFLT1 protein concentrations were also lower in the high group as compared to the medium 
(P = 0.001) or low (P = 0.05) groups (Figure 2.3D).  
  
68 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. Effects of choline treatment on viable cell number, sFLT1 mRNA abundance, and 
sFLT1 protein concentrations in the HTR-8/SVneo cells. A) viable cell counts measured with 
trypan blue exclusion; B) sFLT1 mRNA abundance; C) sFLT1 protein secreted to the cell culture 
medium; and D) intracellular sFLT1 protein concentrations. The HTR-8/SVneo cells were 
cultured in RPMI1640, 2mM L-glutamine and 1.25% fetal bovine serum supplemented with 
three different doses of choline to final total choline concentrations of 8 (low), 13 (medium) and 
28 (high) μM. Cells were cultured at 5% CO2-95% air at 37ºC for 96-h. The same experiment 
was repeated three times. Lowercase letters that differ denote significant difference. Values are 
mean ± SE, n=3 per choline treatment group per experiment. Data were analyzed with one-way 
ANOVA followed post-hoc Fisher’s LSD tests.  
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DISCUSSION  
 In this controlled choline feeding study involving third trimester pregnant women, we 
employed an untargeted approach to identify genes and biological processes within the 
placenta that may be affected by maternal choline intake. We subsequently focused our 
analysis on the impact of maternal choline intake on the placental production of the 
preeclampsia risk marker, sFLT1.    
A higher maternal choline intake suppresses placental expression of sFLT1 
   We show that maternal choline intake alters placental mRNA abundance and maternal 
circulating protein concentrations of sFLT1 with lower levels in the 930 versus the 480 mg/d 
choline intake group. The strong correlation between placental sFLT1 expression and 
circulating sFLT1 protein suggests that choline modifies maternal protein sFLT1 via its effect 
on placental sFLT1 production. Notably, the modulatory role of choline on placental 
production of sFLT1 was confirmed in our human placenta cell culture model which 
demonstrated 20-70 % lower sFLT1 transcript and protein abundance in cells treated with 28 
versus 8 μM choline.   
 Excess sFLT1 is considered to be a contributing factor in the development of placental 
dysfunction and preeclampsia (28, 32). Administration of exogenous sFLT1 produces several 
of the clinical and pathological symptoms (e.g., hypertension, proteinuria and glomerular 
endotheliosis) of preeclampsia in rats (28, 32) and neutralizing antibodies directed against 
sFLT1 can rescue angiogenic deficits in cell culture models (33). In addition, placental 
expression and circulating concentrations, of sFLT1 are elevated in preeclamptic women (34) 
and increased maternal serum sFLT1 predicts preeclampsia several weeks before the onset of 
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the disease (3). As such, supplementing the maternal diet with extra choline to lower 
placental production of sFLT1 may be a therapeutic approach to improve placental function 
and to prevent/mitigate some of the pathological changes that accompany preeclampsia.   
Acetylcholine signaling may be involved in the altered sFLT1 expression by maternal choline 
intake 
The placenta is a nonneuronal tissue that accumulates large amounts of acetylcholine, a 
signaling molecule that can affect cellular proliferation, amino acid transport, vasodilation, 
and parturition (35). Notably, the higher maternal choline intake (930 versus 480 mg/d) 
enhanced placental production of acetylcholine (11) and expression of CHRM4, a cholinergic 
receptor that mediates acetylcholine signaling among pregnant women consuming 930 versus 
480 mg/d choline. Moreover, both acetylcholine signaling components (i.e., acetylcholine and 
CHRM4) were inversely related to placental sFLT1 transcript abundance and maternal 
circulating sFLT1. Collectively, these data suggest that acetylcholine signaling may play a 
regulatory role in the placental production of sFLT1.   
Another mechanism by which maternal choline intake can affect angiogenesis is through 
epigenetic mechanisms (9). Like other angiogenic factors, sFLT1 expression is regulated by 
the methylation state of CG dinucleotides residing in its promoter region (i.e., FLT1 gene) 
(26). Nonetheless, maternal choline intake did not alter FLT1 methylation in the present study 
suggesting that that the observed changes in placental sFLT1 production were independent of 
this epigenetic mark.  
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Maternal choline intake is associated with the altered expression of a wide array of 
angiogenic genes in the placenta 
Despite our focus on sFLT1, it is noteworthy that the whole genome expression 
microarray identified many other genes with roles in circulatory system development and 
angiogenesis that were differentially altered by maternal choline intake. The majority of the 
genes altered in the GO of circulatory system development were downregulated in the 930 
versus 480 mg choline/d group including OXTR which regulates vascular tone (36), PTK2B 
which is involved in endothelial sprouting (37), and COL8A1 and ELN, components of the 
extracellular matrix that mediate vascular morphogenesis (38, 39). Overall, the microarray 
data are consistent with a modulatory role of maternal choline intake on the transcription of 
placental genes with key roles in vascular development. In turn, these data can be used to 
guide additional “proof of principle” studies that seek to confirm a causal role of choline in 
modulating the expression of genes with critical roles in placental vascular function.  
Conclusion 
   A higher maternal choline intake throughout the third trimester of human pregnancy 
suppresses the placental production of sFLT1, an anti-angiogenic factor linked to placental 
dysfunction and preeclampsia. Therefore supplementing the maternal diet with extra choline 
may be a strategy for improving maternal and placental vascular function and/or reducing the 
risk of conditions associated with placental dysfunction. Nonetheless, additional studies that 
supplement with choline across the gestational period, and involve both healthy and 
complicated pregnancies, are required to more thoroughly understand the putative benefits of 
maternal choline supplementation on placental function in humans.  
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Supplemental Figure S2.1. Differentially expressed placental genes in the 930 vs. 480 mg 
choline/d maternal intake group identified by genome wide microarray. A) hierarchical 
clustering of differentially expressed genes. Color scheme: yellow, upregulated in the 930 
mg/d group; blue, downregulated in the 930 mg/d group. B) Fold difference of differentially 
expressed genes in the 930 vs. the 480 mg/d group. Select genes (indicated by asterisks) were 
verified by quantitative real-time PCR. 
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Supplemental Table S2.1. Select gene ontology terms altered in the 930 versus 480 mg 
choline/d maternal intake groups 
Gene Ontology Total Genes 
Changed 
Genes P value 
GO:0046903 secretion 638 17 < 0.001
GO:0046676 negative regulation of insulin secretion 17 3 < 0.001
GO:0022600 digestive system process 46 4 < 0.001
GO:0003001 generation of a signal involved in cell-cell 
signaling 261 8 0.001 
GO:0044089 positive regulation of cellular component 
biogenesis 6 2 0.001 
GO:0051962 positive regulation of nervous system 
development 6 2 0.001 
GO:0051592 response to calcium ion 61 4 0.001 
GO:0048511 rhythmic process 162 6 0.001 
GO:0060341 regulation of cellular localization 363 9 0.001 
GO:0010817 regulation of hormone levels 317 8 0.002 
GO:0014061 regulation of norepinephrine secretion 11 2 0.003 
GO:0048706 embryonic skeletal system development 85 4 0.003 
GO:0003206 cardiac chamber morphogenesis 42 3 0.004 
GO:0017157 regulation of exocytosis 45 3 0.004 
GO:0002920 regulation of humoral immune response 14 2 0.005 
GO:0070482 response to oxygen levels 157 5 0.006 
GO:0007176 regulation of epidermal growth factor 
receptor activity 16 2 0.006 
GO:0006950 response to stress 2184 26 0.007 
GO:0006813 potassium ion transport 165 5 0.007 
GO:0061097 regulation of protein tyrosine kinase 
activity 18 2 0.008 
GO:0042036 negative regulation of cytokine biosynthetic 
process 21 2 0.01 
GO:0051049 regulation of transport 610 10 0.014 
GO:0030855 epithelial cell differentiation 195 5 0.014 
GO:0072358 cardiovascular system development 523 9 0.014 
GO:0072359 circulatory system development 523 9 0.014 
GO:0033002 muscle cell proliferation 70 3 0.015 
GO:0002440 production of molecular mediator of 
immune response 71 3 0.015 
GO:0050433 regulation of catecholamine secretion 26 2 0.015 
GO:0007595 lactation 28 2 0.018 
GO:0006163 purine nucleotide metabolic process 456 8 0.019 
GO:0002576 platelet degranulation 82 3 0.022 
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GO:0048661 positive regulation of smooth muscle cell 
proliferation 32 2 0.023 
GO:0001666 response to hypoxia 149 4 0.024 
GO:0055080 cation homeostasis 308 6 0.025 
GO:0045768 positive regulation of anti-apoptosis 36 2 0.028 
GO:0051952 regulation of amine transport 36 2 0.028 
GO:0045761 regulation of adenylate cyclase activity 95 3 0.032 
GO:0046034 ATP metabolic process 96 3 0.033 
GO:0006875 cellular metal ion homeostasis 244 5 0.033 
GO:0006916 anti-apoptosis 245 5 0.034 
GO:0003013 circulatory system process 254 5 0.039 
GO:0008015 blood circulation 254 5 0.039 
GO:0007186 G-protein coupled receptor protein 
signaling pathway 530 8 0.04 
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Supplemental Figure S2.2. CpG methylation of the proximal promoter region of FLT1. A: 
Sequence map of the amplified region. Result of a specific CpG unit was included in the 
analysis if measurement success rate > 75%. CpG units1-4 were included in final analysis. B: 
CpG methylation of individual CpG units that were included in the analysis. C: Average CpG 
methylation across the 4 CpG units. White bar: 480 mg choline/d group. Black bar: 930 mg 
choline/d group. Values are mean ±SE. n=12/choline group. Data were analyzed with general 
linear models. CpG, cytosine-phosphate-guanine; FLT1, fms-like tyrosine kinase-1 
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CHAPTER 3 
Pregnancy induces transcriptional activation of the peripheral innate immune system 
and increases oxidative DNA damage among healthy third trimester pregnant women* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Jiang X, Bar HY, Yan J, West AA, Perry CA, Malysheva OV, Devapatla S, Pressman E, 
Vermeylen FM, Wells MT, Caudill MA.Pregnancy Induces Transcriptional Activation of the 
Peripheral Innate Immune System and Increases Oxidative DNA Damage among Healthy 
Third Trimester Pregnant Women. PLoS One. 2012;7(11):e46736. 
doi:10.1371/journal.pone.0046736.  
Authors hold the copyright of this paper. 
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ABSTRACT 
Pregnancy induces physiological adaptations which may involve, or contribute to, 
alterations in the genomic landscape. Pregnancy also increases the nutritional demand for 
choline, an essential nutrient that can modulate epigenomic and transcriptomic readouts 
secondary to its role as a methyl donor. Nevertheless, the interplay between human pregnancy, 
choline and the human genome is largely unexplored.  
As part of a controlled feeding study, we assessed the influence of pregnancy and choline 
intake on maternal genomic markers. Healthy third trimester pregnant (n=26, wk 26-29 
gestation) and nonpregnant (n=21) women were randomized to choline intakes of 480 mg/day, 
approximating the Adequate Intake level, or 930 mg/day for 12-weeks. Blood leukocytes 
were acquired at study week 0 and study week 12 for microarray, DNA damage and global 
DNA/histone methylation measurements. A main effect of pregnancy that was independent of 
choline intake was detected on several of the maternal leukocyte genomic markers.  
Compared to nonpregnant women, third trimester pregnant women exhibited higher (P<0.05) 
transcript abundance of defense response genes associated with the innate immune system 
including pattern recognition molecules, neutrophil granule proteins and oxidases, 
complement proteins, cytokines and chemokines. Pregnant women also exhibited higher 
(P<0.001) levels of DNA damage in blood leukocytes, a genomic marker of oxidative stress.  
No effect of choline intake was detected on the maternal leukocyte genomic markers with the 
exception of histone 3 lysine 4 di-methylation which was lower among pregnant women in 
the 930 versus 480 mg/d choline intake group.     
Pregnancy induces transcriptional activation of the peripheral innate immune system and 
increases oxidative DNA damage among healthy third trimester pregnant women.  
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INTRODUCTION 
Pregnancy induces several physiological adaptations to meet the needs of the 
developing fetus and the health requirements of the mother. Many of these 
pregnancy-induced physiologic adaptations may involve, or contribute to, alterations in the 
genomic landscape. Nevertheless, very few studies have examined the interplay between 
pregnancy and the human genome.   
A prominent change during pregnancy is the modulation of the immune system to 
accommodate the presence of a semiallogeneic fetus (1). In normal pregnancy, there is a shift 
in the balance of T lymphocytes, mediators of the adaptive cellular immune response, 
towards a Th2 (immunosuppressive) phenotype with an anti-inflammatory cytokine profile.  
However, there is also a need to defend against pathogens for the mother-fetus dyad (2). 
Neutrophils, mediators of the innate immune response that play a key role in the first line of 
defense against pathogens, increase in peripheral blood during pregnancy (3). Nevertheless, it 
is unclear as to whether these neutrophils are activated. In vitro studies showed that 
neutrophils from pregnant women exhibited reduced microbial killing and chemotaxis (4, 5). 
However, flow cytometry studies showed that several neutrophil surface markers were higher 
in the pregnant state indicating neutrophil activation (6, 7). Thus, studies that profile the 
transcriptome of blood leukocytes are needed to better understand the status of the immune 
system during human pregnancy. 
A greater susceptibility to oxidative stress, mostly because of the mitochondria-rich 
placenta (8), is another characteristic of human pregnancy. Oxidative stress can cause DNA 
damage (9), which in turn can lead to aberrant gene expression and apoptosis. Although 
higher levels of DNA damage are detected among women with complicated pregnancies (9, 
10), it is unclear whether DNA damage is elevated in normal pregnancy. Studies that examine 
indicators of DNA damage are needed to advance understanding of redox balance during 
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normal pregnancy and to inform nutritional therapeutic opportunities. 
    Pregnancy is also associated with an increased demand for methyl donors to 
maintain epigenetic marks in the expanding maternal and fetal tissues (11). DNA and histone 
methylation play a fundamental role in regulating chromatin structure, stability and gene 
expression (12, 13). A major source of methyl groups for DNA and histone methylation is the 
essential micronutrient choline, which is recommended at an intake level of 450 mg/d during 
pregnancy (14). Notably, we previously demonstrated in third trimester pregnant women that 
consumption of choline at approximately two times the current intake recommendation (i.e., 
930 versus 480 mg/d) substantially altered epigenetic marks (15) and transcriptome readouts 
in fetal derived tissues (i.e., placental and cord blood leukocytes). Nonetheless, it remains to 
be determined if a maternal choline intake exceeding current recommendations can alter 
genomic marks in the mothers themselves.  
   The aims of the current study were to investigate the influence of both pregnancy and 
maternal choline intake on leukocyte genomic markers. To accomplish these aims, we 
examined genome-wide gene expression, DNA damage, and global DNA/histone methylation 
in blood leukocytes obtained from third trimester pregnant women and nonpregnant control 
women enrolled in a 12-week controlled feeding study (16).  
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MATERIALS AND METHODS 
Study Participants 
Healthy third trimester (week 26-29 gestation) singleton pregnant women and 
nonpregnant control women aged ≥ 21y were recruited from Ithaca, New York, and 
surrounding areas between January 2009 and October 2010. Entry into the study was 
contingent upon good health status, no tobacco or alcohol use, and a willingness to comply 
with the study protocol. Twenty-six of the 29 pregnant women and 21 of the 22 nonpregnant 
women who started the study completed it. Information regarding the study participants and 
the CONSORT flowchart have been reported previously (16).  
Description of procedures 
Study Design and Diet 
This was a 12-week controlled feeding study in which pregnant (n=26) and nonpregnant 
(n=21) women were randomized to either 480 (an intake level that approximates the choline 
adequate intake, AI) or 930 mg choline/d. The choline was derived from the diet (380 mg/d) 
plus supplemental choline chloride (either 100 or 550 mg choline/d for the 480 or 930 mg/d 
intake levels, respectively). Throughout the 12-wk study, the participants consumed a 7-day 
cycle menu. Choline-free prenatal multivitamins and docosahexaenoic acid supplements were 
provided daily as detailed in Yan et al (16). The fact that all participants consumed the same 
diet and supplements makes this study particularly suitable to examining the effects of 
pregnancy on a wide-array of genomic and metabolic endpoints. 
Sample collection 
Blood samples were obtained at study-baseline (week 0) and study-end (week 12). 
Fasting (10-h) peripheral blood mononuclear cells (PBMC, including lymphocytes and 
monocytes) samples were retrieved with Vacutainer CPT tubes (BD, Franklin Lakes, NJ); 
whole blood, leukocyte and plasma samples were retrieved with EDTA tubes (BD) as 
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previously described (16, 17). 
Analytical measurements 
Complete blood counts were conducted with 1mL whole blood using an AcT diff 2 
hematology analyzer (Beckman Coulter, Brea, CA) according to the manufacturer’s 
instructions. 
Total RNA purification was performed with a commercially available kit (RNeasy Mini 
kit, Qiagen, Valencia, CA) as previously detailed (15). The integrity of the RNA samples was 
determined using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). 
Only samples of an RNA Integrity Number (RIN) >8.0 were included for microarray. There 
were 12 sets (a set includes both a wk-0 and a wk-12 measurement) of samples from pregnant 
participants (n= 6/choline intake group) and 10 sets of samples from nonpregnant participants 
(n = 5/choline intake group) that passed the RIN cutoff.  
Gene expression profiling was performed using the Whole Human Gene Expression 
Microarray 4×44K (Agilent) in the samples that met the RIN cutoff. Antisense RNA 
amplification and cyanine-3 labeling was performed with an Amino Allyl MessageAmp II 
aRNA amplification kit (Ambion Inc., Grand island, NY). Microarray hybridization was 
performed at 65ºC for 17-h in an Agilent Microarray Hybridization oven. Microarray 
scanning was performed in an Agilent Scanner (G2505C) and the images were extracted 
using Agilent Feature Extraction Software 10.5. Data normalization was performed using 
log2 transformation and median normalization. An extension of the Laplace approximation 
EM Microarray Analysis (LEMMA) package based on the R software platform 
(http://www.R-project.org) (18) developed by Bar et al. (19, 20) was used to detect 
differentially expressed genes. The version used here (unpublished data) can sensitively 
detect differentially expressed genes, as it takes into account not only mean differences, but 
also variational differences between the comparison groups. Using this method we were able 
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to increase the number of discoveries of differentially expressed genes, relative to other 
methods that do not account for differential variation. The differentially expressed genes 
were declared by controlling the false discovery rate (FDR) with Benjamini-Hochberg (BH) 
correction <0.05 and expression fold difference >2. Differentially expressed genes were 
classified according to their gene ontology (GO) using High-Throughput GoMiner (21). 
Hierarchical clustering was conducted with MultiExperiment Viewer (22, 23). Microarray 
results of select genes were verified using quantitative real-time PCR. All data is MIAME 
compliant. The data has been deposited in a MIAME compliant database NCBI's Gene 
Expression Omnibus (24) as detailed on MGED Society website 
http://www.mged.org/Workgroups/MIAME/miame.html, and are accessible through GEO 
Series accession number GSE36532 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE36532).  
  Reverse transcription and quantitative real-time PCR were performed as previously 
described in the samples used for microarrays (25). Data are expressed using the delta delta 
Ct method (26) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is used as the 
housekeeping gene.  
Circulating tumor necrosis factor alpha (TNFα) and interleukin 6 (IL6) were measured 
in EDTA plasma with commercially available ELISA kits (R&D systems, Minneapolis, MN) 
according to the manufacturer’s instructions.   
    Peripheral blood mononuclear cell (PBMC) DNA damage was measured in duplicate via 
the alkaline version of single-cell gel electrophoresis (COMET assay). Sample preparation 
was performed as described previously (17). DNA migration from the nucleus was visualized 
(75 cells/sample) with an Olympus BX-50 light microscope and a high resolution QImaging 
Retiga EXi cooled CCD camera. Photos were acquired using the MetaMorph Premier (ver. 
7.0) software (Molecular Devices, Sunnyvale, CA) after staining with SYBR Gold 
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fluorescent dye (Invitrogen, Grand Island, NY). Percent tail DNA (defined as the proportion 
of DNA that has migrated from the nucleus) was used as an index of DNA damage and was 
calculated using the software Komet 6.0 (Andor Technology, South Windsor, CT).  
Global DNA methylation was measured in leukocytes using liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) as described by Song et al. (27) 
with modification based on our instrumentation (17). Global DNA methylation 
[5-methyl-2'-deoxycytidine (5mdC)] is expressed as a percentage of 2’-deoxyguanosine 
(representing total 2’-deoxycytidine).  
Global histone methylation was measured with western blots as described previously (15). 
Leukocyte samples (200 μL) were suspended in 0.2N hydrochloric acid at 4°C overnight. The 
extracts were separated by SDS-PAGE and transferred to Immobilon-FL polyvinylidene 
fluoride transfer membranes. Membranes were incubated with corresponding primary and 
secondary antibodies (15). Target protein bands were quantified with the LI-COR Odyssey® 
imaging system (LI-COR, Lincoln, NE) and expressed as the ratio of intensity of the histone 
epigenetic mark to the reference total histone 3 proteins.  
Ethics 
The study was approved by the Cornell University and Cayuga Medical Center 
Institutional Review Boards for Human Participants and written informed consent was 
obtained from every participant prior to study entry. The study was registered at 
clinicaltrials.gov as NCT01127022.  
Statistical analysis 
The effect of pregnancy on dependent variables (e.g. DNA damage, epigenetic marks, 
gene expression) was assessed at study-baseline (wk-0) and study-end (wk-12) separately 
with general linear models (GLMs). Pregnancy status and choline intake were included as 
independent variables and all two-way interactions were tested. The effect of choline intake 
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on the genomic markers was assessed at study-end in a similar manner with study-baseline 
data included as a covariate. All of the analyses included leukocyte sub-population (e.g. the 
percentage of granulocytes) as a covariate with the exception of the DNA damage variable 
which only contains PBMCs. Additional candidates for entry as covariates into the statistical 
models are listed in Table 3.1. Covariates and interaction terms that did not achieve a 
statistical significance of P < 0.05 were removed from the models in a stepwise process. 
Plots and histograms of the residuals were used to assess normality in the models. 
Dependent variables that deviated from the normal distribution (e.g. global histone 
methylation and quantitative PCR data) were logarithmically transformed to meet the 
assumption of normality. Differences were considered to be significant at P ≤ 0.05; P < 0.10 
was considered to be indicative of trends. Values are presented as means ± SEM. If covariates 
were retained in the final models, the values presented are predicted means; P values are 
two-tailed. All analyses were performed using SPSS (release 18.0 for Windows, SPSS Inc, 
Chicago, IL). 
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Table 3.1. Baseline (study week 0) characteristics of third trimester pregnant women and nonpregnant women randomized to either the 480 or 
930 mg/d choline intake groupa 
 Pregnant Nonpregnant 
 480 mg/d (n = 13) 930 mg/d (n = 13) 480 mg/d (n = 10) 930 mg/d (n = 11) 
Age, yr (range) 29 (25-33) 28 (22-34) 28 (21-37) 29 (21-40) 
Ethnicity, Caucasian/African American/ 
Latino/Asian/Other 
9/0/2/1/1 7/1/2/3/0 8/1/1/0/0 6/1/1/1/2 
BMIb, kg/m2 (range) 23.6 (20.2 – 31.9) 23.6 (19.9 – 29.8) 23.6 (19.6 – 27.3) 23.5 (18.2 – 29.8) 
Education, high school/college 1/12 3/10 3/7 3/8 
Physical activity, usual daily activity/ 
exercise > 3 times per wk/ unknown 
5/7/1 1/10/2 2/8/0 1/9/1 
Vitamin supplement consumption, yes/noc 11/2 11/2 2/8 5/6 
aDetailed in Yan et al, 2012 [16].  
bFor pregnant women, this parameter represented pre-pregnancy BMI 
cP < 0.01 between pregnant and nonpregnant women, Chi-square test
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RESULTS 
Participant characteristics 
The characteristics of the study population at study-baseline (wk-0) are shown in 
Table 3.1. Third trimester pregnant and nonpregnant women did not differ in their age, 
ethnicity/race, pre-pregnancy BMI, education, or physical activity. However, vitamin 
supplement consumption was greater (P < 0.01) among pregnant women. No differences (P > 
0.13) in the baseline characteristics were detected among the choline intake groups (Table 
3.1). All pregnant women delivered their babies at term without major complications and 
their babies were apparently healthy (16).  
 
The effects of choline 
  No main effects of choline (P > 0.05) were detected for any of the dependent variables.  
However, choline intake interacted (P = 0.03) with pregnancy status to affect H3K4me2. 
After stratifying by pregnancy status, H3K4me2 was higher (P = 0.04, controlling for the 
leukocyte sub-populations) in the 930 versus 480 mg choline/d group among pregnant 
women (Figure 3.1). This relationship did not achieve statistical significance among 
nonpregnant women (P = 0.12). No additional choline × pregnancy interactions (P > 0.05) 
were detected. 
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The effects of pregnancy 
 A main effect of pregnancy was detected for several of the dependent variables at 
study-baseline and study-end (values taken after controlled feeding and choline 
randomization) as described in subsequent text. The pregnancy effect was not modified by 
choline intake (i.e., no significant pregnancy × choline interactions were detected for any of 
the variables) at study-end indicating an effect of pregnancy that is independent of choline 
intake. 
Peripheral blood leukocyte counts  
Granulocytes and monocytes are important components of the innate immune system. 
Third trimester pregnant women exhibited higher (P < 0.01) granulocyte counts (the majority 
Figure 3.1. Effect of choline intake on peripheral blood leukocyte H3K4me2. The 
relative abundance of H3K4me2 at study-end in third trimester pregnant women (right) 
and nonpregnant women (left) consuming 930 versus 480 mg choline/d. White bar: 480 
mg choline/d group, black bar: 930 mg choline/d group. n=10-13/ choline intake and 
pregnancy status. Values are predicted means ± SEM. Analyzed with general linear 
models. 
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of which was neutrophils) and borderline higher (P < 0.09) monocyte counts than 
nonpregnant women at both study-baseline and study-end. Lymphocyte count was not altered 
by pregnancy (Table 3.2).  
Leukocyte genome wide expression 
There were 1068 upregulated and 244 downregulated genes at study-baseline, and 1048 
upregulated and 280 downregulated genes at study-end, in pregnant versus nonpregnant 
women (Figure 3.2). Of these ~1300 differentially expressed genes, 932 were altered at both 
study-baseline and study-end (Supplemental Table S3.1, available at 
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0046736#s5). The 
differential expression of select genes was verified by quantitative PCR (Table 3.3). Gene 
expression did not differ between study-end and study-baseline, suggesting that the leukocyte 
gene expression profile was stable throughout the third trimester of pregnancy.  
 
 
Figure 3.2. Venn diagram of differentially expressed genes by pregnancy. This figure presents 
the number of genes differentially expressed in third trimester pregnant versus nonpregnant 
women at study-baseline (circle on the left) and study-end (circle on the right). The number 
of genes altered both at study-baseline and study-end are presented in the intersecting area of 
the two circles. Color scheme: blue represents low expression and yellow represents high 
expression. n=12 for pregnant women; n=10 for nonpregnant women. Analyzed with the 
LEMMA statistical package. 
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Table 3.2. Peripheral blood leukocyte counts in third trimester pregnant women and nonpregnant women at the beginning and end of the 
controlled feeding study. 
 
 
 
 
 
 
 
 
 
Data were analyzed using general linear models.
 
Study-baseline Study-end 
 
Pregnant Nonpregnant P value Pregnant Nonpregnant P value 
 
(n=26) (n=21)  (n=26) (n=21)  
Leukocytes (× 103/μL) 9.8 ± 0.5 6.1 ± 0.2 < 0.01 9.7 ± 0.5 6.3 ± 0.3 < 0.01 
Lymphocytes (× 103/μL) 1.8 ± 0.1 1.9 ± 0.1 0.30 2.0 ± 0.1 2.1 ± 0.1 0.70 
Monocytes (× 103/μL) 0.3 ± 0.03 0.2 ± 0.02 < 0.01 0.3 ± 0.02 0.2 ± 0.02 0.09 
Granulocytes (× 103/μL) 7.7 ± 0.4 4.0 ± 0.2 < 0.01 7.4 ± 0.4 3.9 ± 0.2 < 0.01 
Granulocyte (%) 78.2 ± 0.9 65.4 ± 1.4 < 0.01 75.4 ± 0.9 62.5 ± 1.6 < 0.01 
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Table 3.3 Quantitative PCR verification of microarray results of genes differentially expressed in third trimester pregnant women (n=12) and 
nonpregnant women (n=10) at the end of the controlled feeding study. 
Gene 
symbol 
Gene name Function Total transcript abundance 
Transcript abundance 
/percent granulocyte 
Transcript abundance 
/granulocyte count 
 
  Fold change P value Fold change P value Fold change P value 
OLFM4 Olfactomedin 4 Cell adhesion 64 <0.01 49 <0.01 32 <0.01 
LTF Lactoferrin Host defense 39 <0.01 30 <0.01 23 <0.01 
ELANE Elastase 
Virulence factor 
degradation 
34 <0.01 26 <0.01 18 <0.01 
DEFA4 Defensin, alpha 4 Host defense 25 <0.01 20 <0.01 15 <0.01 
 
Data were analyzed with general linear models. Fold change was calculated as the average transcript abundance in pregnant women/ the average 
transcript abundance in nonpregnant women. Samples were the same as the ones used for microarray. Microarray and qPCR results are 
consistent.
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The GO analyses conducted at study-baseline and study-end showed similar biological 
themes: thus, only the GO results at study-end are presented. At study-end, 246 molecular 
function categories were altered (P < 0.01) (Supplemental Table S3.2, available at 
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0046736#s5), ~40% 
of which was related to immune response. The GO of defense response (GO: 0006952) 
showed the most significant alteration. Of the 112 defense response genes altered, 105 were 
upregulated in third trimester pregnant women as compared to nonpregnant women (Figure 
3.3). To evaluate whether the elevated expression of defense response genes was mediated at 
least in part by the activation of granulocytes, we used leukocyte sub-population as a 
covariate in the statistical models. After adjusting for leukocyte sub-populations, the greater 
expression of the defense response genes among pregnant women was maintained (examples 
are shown in Table 3.3 and 3.4), suggesting that the higher expression of defense response 
genes was not solely a function of higher granulocyte counts, but also due to enhanced 
activation of the granulocytes.  
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  Figure 3.3. Hierarchical clustering of differentially expressed immune defense genes 
(GO: 0006952) in pregnant (n=12) versus nonpregnant (n=10) women.  
 This figure presents the hierarchical clustering of 112 differentially expressed 
immune defense genes in third trimester women versus nonpregnant women (reference 
group) at the beginning and end of the controlled feeding study. Color scheme: blue 
represents low expression and yellow represents high expression. n=12 for pregnant 
women; n=10 for nonpregnant women. Analyzed with Euclidean distances using 
MultiExperiment Viewer.  
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Table 3.4. Select list of genes involved in defense response that were upregulated in third 
trimester pregnant women at the end of the controlled feeding study. 
Gene 
symbol 
Gene name Category 
Fold change 
(unadjusted) 
Fold change 
(adjusted) 
CD14 CD14 molecule Surface marker 2.30 1.77 
TLR1 Toll-like receptor 1 TLR signaling pathway 2.16 1.79 
TLR4 Toll-like receptor 4 TLR signaling pathway 2.47 1.94 
TLR5 Toll-like receptor 5 TLR signaling pathway 3.07 2.43 
TLR6 Toll-like receptor 6 TLR signaling pathway 2.51 1.97 
MYD88 
Myeloid differentiation 
primary response gene 
(88) 
TLR signaling pathway 2.02 1.51 
ELANE 
Elastase, neutrophil 
expressed 
Azurophil granule  11.05 13.77 
MPO Myeloperoxidase Azurophil granule  7.25 7.44 
AZU1 Azurocidin 1 Azurophil granule  2.94 2.93 
CTSG Cathepsin G Azurophil granule  7.50 7.03 
DEFA1 Defensin, alpha 1 Azurophil granule  4.76 3.72 
DEFA3 
Defensin, alpha 3, 
neutrophil-specific 
Azurophil granule  7.53 4.97 
DEFA4 
Defensin, alpha 4, 
corticostatin 
Azurophil granule  26.95 25.81 
LTF Lactotransferrin Specific granule protein 35.51 26.33 
CAMP 
Cathelicidin 
antimicrobial peptide 
Specific granule protein 17.48 15.59 
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C1QB 
Complement 
component 1, q 
subcomponent, B 
Complement system 3.35 2.62 
CR1 
Complement 
component (3b/4b) 
receptor 1 
Complement system 3.20 2.50 
C2 
Complement 
component 2 
Complement system 3.58 2.80 
IL1B Interleukin 1, beta Cytokine signaling 2.78 2.14 
IL1R1 
Interleukin 1 receptor, 
type I 
Cytokine signaling 2.42 1.77 
IL8RB 
Interleukin 8 receptor, 
beta 
Cytokine signaling 2.86 2.23 
IL8RA 
Interleukin 8 receptor, 
alpha 
Cytokine signaling 2.81 2.19 
P values < 0.05 with or without adjusting for leukocyte sub-populations as analyzed with 
general linear models or the LEMMA statistical package, respectively. Fold change was 
calculated as the average transcript abundance in pregnant women / the average transcript 
abundance in nonpregnant women in the microarrays.
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Among pregnant women, several components of the toll-like receptor (TLR) signaling 
pathway were upregulated, including the genes encoding TLR1, 4, 5, 6; the CD molecule 14 
(CD14), a major surface marker of neutrophils and monocytes that interacts with TLR4; and 
myeloid differentiation primary response gene 88 (MYD88). The TLRs are pattern 
recognition molecules on immune cells (e.g., neutrophils) that recognize pathogenic elements 
(e.g., lipopolysaccharides) and illicit a signaling cascade involving MYD88 that results in the 
increased production of proinflammatory cytokines such as interleukin 1β (IL1β) and the 
chemokine interleukin 8 (IL8) (28, 29). The increased IL8 production favors chemotaxis and 
survival of the neutrophils (30).  
Third trimester pregnant women also exhibited higher expression of genes encoding: (i) 
the microbicidal proteins stored in the neutrophil granules [e.g. the azurophil proteins elastase 
(ELANE), alpha-defensins (DEFA) and specific granule proteins lactoferrin (LTF) and 
cathelicidin (CAMP)]; (ii) the complement proteins involved in innate humoral immune 
response [e.g. complement component 1, q subcomponent, B chain (C1QB), complement 
component 2 (C2) and complement component (3b/4b) receptor 1 (CR1)]; (iii) proteins 
involved in neutrophil superoxide anion production [e.g. the NADPH oxidase complex 
neutrophil cytosolic factors (NCF), and myeloperoxidase (MPO)]; and (iv) the 
proinflammatory cytokines (e.g. IL1B). The GO of TNF (GO:0032640) and IL6 
(GO:0032675) production were also upregulated.  
Only a few (~8) immune response genes were downregulated among pregnant women after 
controlling for the leukocyte sub-populations. The repressed genes were mostly associated 
with the adaptive immune response (Table 3.5) and included: (i) the transmembrane 
glycoprotein CD1 family members CD1c and CD1e molecules, which present primary lipid 
and glycolipid antigens to T cells (31); (ii) the chemokine (C-C motif) receptors CCR6 and 
CCR9, which are preferably expressed by T cells (32, 33); (iii) CD70 molecule, a surface 
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antigen on activated T and B lymphocytes (34) and (iv) B-cell linker protein (BLNK), which 
plays an important role in B cell development and receptor signaling (35). 
Plasma TNFα and IL6 
Circulating concentrations of TNFα were higher among pregnant women at study-end 
(1.18 ± 0.09 vs. 0.94 ± 0.07 pg/mL, P=0.05) but not at study-baseline (1.19 ± 0.16 vs. 0.94 ± 
0.09 pg/mL, P=0.19). IL6 was elevated among pregnant women at both study-baseline (1.22 
± 0.19 vs. 0.73 ± 0.07 pg/mL, P=0.02) and study-end (1.50 ± 0.15 vs. 0.73 ± 0.10 pg/mL, 
P<0.01) (Figure 3.4). The higher circulating concentrations of TNFα and IL6 among 
pregnant women at study-end corresponded with the microarray GO results showing 
upregulation of TNF and IL6 production.  
 
 
 
 
 
 
 
Figure 3.4. Plasma TNFα and IL6 concentrations. Plasma concentrations of TNFα and 
IL6 in third trimester pregnant versus nonpregnant women at study-baseline (A) and 
study-end (B). White bar: nonpregnant women (n=21); black bar: pregnant women 
(n=26). Values are means ± SEM. Analyzed with general linear models. 
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Table 3.5. Genes involved in adaptive immune response that were downregulated in third 
trimester pregnant women at the end of the controlled feeding study. 
Gene 
symbol 
Gene name Function 
Fold change 
(unadjusted) 
Fold change 
(adjusted) 
CD70 CD70 molecule 
Activated T and B cell 
marker 
0.47 0.61 
CD1C CD1c molecule Antigen presentation 0.46 0.63 
CD1E CD1e molecule Antigen presentation 0.42 0.55 
CCR6 
chemokine (C-C 
motif) receptor 6 
T cell recruitment 0.34 0.54 
CCR9 
chemokine (C-C 
motif) receptor 9 
T cell recruitment 0.50 0.47 
BLNK B cell linker B cell receptor signaling 0.38 0.47 
P values < 0.05 with or without adjusting for leukocyte sub-populations as analyzed with 
general linear models or the LEMMA statistical package, respectively. Fold change was 
calculated as the average transcript abundance in pregnant women / the average transcript  
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Leukocyte percent tail DNA 
Third trimester pregnant women had significantly higher (P < 0.01) percent tail DNA 
than nonpregnant women at study-baseline and study-end (Table 3.6). The higher percent tail 
DNA represents greater DNA strand breakage due to oxidative stress. 
Leukocyte global histone and DNA methylation 
Third trimester pregnant women (versus nonpregnant women) had lower levels of the 
transcription activation histone mark H3K4me2 (P < 0.01), and the transcription repression 
mark H3K9me2 (P = 0.05) at study-baseline and study-end (not controlling for leukocyte 
sub-populations) (Figure 3.5, A and C). However, after controlling for leukocyte 
sub-populations, the effect of pregnancy disappeared (Figure 3.5, B and D), suggesting that 
the alterations in leukocyte H3K9me2 and H3K4me2 during pregnancy were a function of 
the shift in the leukocyte sub-populations and that different leukocyte cell types may have a 
different abundance of these histone modifications. Global DNA methylation (study-baseline 
or study-end) was not altered (P > 0.38) by pregnancy (Table 3.6).  
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Table 3.6. Leukocyte DNA damage and global DNA methylation in third trimester pregnant women and nonpregnant women consuming 480 or 
930 mg choline/d at the beginning and end of the controlled feeding study. 
 
Pregnant Nonpregnant 
 
480 mg/d 930 mg/d Total 480 mg/d 930 mg/d Total 
 
(n=13) (n=13) (n=26) (n=10) (n=11) (n=21) 
Percent tail DNA 
     
Study-beginning 44.9 ± 3.6 43.5 ± 4.8 44.3 ± 2.9* 26.4 ± 2.9 27.8 ± 4.0 27.1 ± 2.5 
Study-end  33.2 ± 4.6 43.5 ± 4.8 38.3 ± 3.4* 20.6 ± 1.9 24.9 ± 1.5 22.9 ± 1.6 
DNA methylation 
     
Study-beginning  5.1 ± 0.2 5.2 ± 0.2 5.1 ± 0.1 4.9 ± 0.2 5.2 ± 0.2 5.1 ± 0.1 
Study-end 5.2 ± 0.2 5.1 ± 0.2 5.1 ± 0.1 5.0 ± 0.1 4.8 ± 0.2 4.9 ± 0.1 
Data were analyzed with general linear models. *P < 0.01 between pregnant and nonpregnant women. 
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Figure 3.5. Peripheral blood leukocyte histone modification marks H3K4me2, H3K9me2 
and H3K27me3. (A) and (C), histone modifications in third trimester pregnant versus 
nonpregnant women without controlling for percent granulocytes at study-baseline and 
study-end, respectively (B) and (D), histone modifications in third trimester pregnant 
versus nonpregnant women controlling for percent granulocytes at study-baseline or 
study-end, respectively. White bar: nonpregnant women (n=21), black bar: pregnant 
women (n=26). Data are predicted means ± SEM. Analyzed with general linear models. 
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DISCUSSION 
Genomic markers were investigated among healthy third trimester pregnant and 
nonpregnant control women to advance the understanding of pregnancy induced alterations in 
immune response, redox balance, and epigenomic stability. The effect of maternal choline 
intake on these genomic markers was also investigated secondary to the role of choline as a 
methyl donor. Under both uncontrolled (study-baseline) and controlled (study-end) dietary 
conditions, our data demonstrate that healthy third trimester pregnant women experience 
transcriptional activation of the peripheral innate immune system and elevated oxidative 
stress as indicated by higher DNA damage. Our data also indicate that a choline intake 
exceeding current dietary recommendations does not alter blood leukocyte genomic markers, 
except for H3K4me2 among third-trimester pregnant women.  
The effects of pregnancy 
Immune Function  
 Pregnant women experienced an elevation in the transcript abundance of 105 leukocyte 
defense response genes as compared to nonpregnant control women. The majority of 
upregulated defense genes were neutrophil-associated genes including neutrophil surface 
markers (e.g. CD14), pattern recognition molecules, cytokines, chemokines, neutrophil 
granule proteins, complement proteins and neutrophil oxidases. Importantly, the greater 
transcription of these host defense genes among third trimester pregnant women persisted 
after controlling for the leukocyte sub-populations, indicating transcriptional activation, 
rather than suppression, of individual neutrophils. The activation of peripheral neutrophils 
(and the innate immune system) during the last third of human pregnancy may serve as a 
compensatory mechanism to protect the maternal-fetal dyad against pathogens when the 
adaptive immune response is suppressed. Overall our data provide a blueprint of pregnancy 
induced changes in the peripheral blood transcriptome and elucidate new pathways and 
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molecules that function in the modulation of the immune system during the third trimester of 
human pregnancy.  
Oxidation stress and DNA damage 
 Leukocyte DNA damage was approximately two times greater among third trimester 
pregnant women than nonpregnant control women. This elevation in DNA damage among 
pregnant women may arise from increases in oxidative stress particularly as pregnancy 
advances (9). Healthy pregnant women were previously thought to overcome oxidative stress 
through upregulation of antioxidation machinery (36, 37). However, our study suggests that 
DNA damage commonly occurs throughout the last third of uncomplicated pregnancies.  
 It is noteworthy that oxidative stress and immune activation are interrelated. Neutrophils 
are both activated by, and a producer of, reactive oxygen species. TLR4 signaling is enhanced 
by reactive oxygen species, leading to sustained production of proinflammatory proteins, 
which in turn maintain oxidative stress (38). In addition, activated neutrophils are a 
significant source of reactive oxygen species via the activity of NADPH oxidase and 
myeloperoxidase (MPO) (39), which were both upregulated among pregnant women in our 
study. Although the increased oxidative stress appears to be a normal event of pregnancy, the 
DNA damage by reactive oxygen species can lead to genomic instability, aberrant gene 
expression and apoptosis (40, 41). Additional studies are thus needed to address the health 
effects of pregnancy-induced leukocyte DNA damage and whether the DNA damage resolves 
after delivery.  
The effects of choline intake 
A higher maternal choline intake increased dimethylation of H3K4, which is indicative 
of active transcription (42). To the best of our knowledge, this is the first report in humans 
that choline intake affected an epigenetic mark of histones obtained from leukocytes of 
pregnant women. Nevertheless, we did not observe a corresponding change in leukocyte gene 
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expression by choline intake within the time frame of this study and no other genomic marks 
were affected by maternal choline intake. Thus, unlike the genomic marks (e.g., DNA 
methylation (15) and transcriptome profiles (unpublished data) of developing fetal-derived 
tissues (i.e., placenta and cord blood leukocytes) which are highly responsive to maternal 
choline intake, genomic markers of maternal-derived tissue may be relatively unresponsive to 
changes in maternal choline intake. 
Limitations 
Our study has two major limitations. First, data collection was limited to the third 
trimester of pregnancy; thus, additional studies are needed to address the effects of pregnancy 
and maternal choline intake on maternal genomic marks in earlier stages of gestation as well 
as in the postnatal period. Second, genomic marks from peripheral blood sampling do not 
necessarily reflect genomic marks in other tissues. Nonetheless, blood transcript profiling is 
considered a robust tool for assessing the status of the human immune system (43-45). 
Conclusions 
In summary, the last third of human pregnancy is characterized by transcriptional 
activation of the neutrophils and elevations in maternal leukocyte oxidative DNA damage. 
These findings are consistent with an upregulation of the peripheral innate immune system 
which plays a central role in protecting the maternal and fetal dyad against pathogens. 
Additional studies are needed to delineate the long-term functional consequences of these 
genomic alterations and to investigate the relationship between these genomic marks and 
complicated pregnancy. 
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AFTERWORD 
 
The findings of my dissertation advance current understanding of the impact of maternal 
choline intake on genomic readouts in humans and suggest that a choline intake exceeding 
current recommendations may enhance maternal and fetal wellbeing. In particular, we show 
robust effects of maternal choline intake on the genomic landscape of the placenta with 
evidence of functional consequences on the neonates’ response to stress and the vasculature 
of the placenta. In addition, the study findings illustrate the importance of employing an 
untargeted exploratory approach to unveil physiologic processes previously unconnected to 
choline.     
 
Maternal choline intake can influence fetal epigenetic markers 
Animal studies have demonstrated that gestational choline intake can influence the 
epigenome of the offspring, which contributes at least in part to functional improvements in 
neurogenesis, angiogenesis and cancer prognosis (1, 2). Our study is the first to show that 
maternal choline intake also affects fetal epigenetic programming in humans. The epigenetic 
alterations in genes that regulate the HPA axis and cortisol production were especially 
responsive to maternal choline intake and provide mechanistic insights as to how a higher 
maternal choline intake (930 versus 480 mg choline/d) can attenuate stress reactivity and 
cortisol production in the fetal compartment. In addition, the epigenetic alteration in cortisol 
regulating genes implies that maternal choline intake may beneficially program the HPA axis. 
Based on prior work (3-5), a dampening of the HPA axis in response to stress would be 
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expected to reduce susceptibility to stress induced illness and chronic conditions such as 
hypertension and insulin resistance later in life.  
 
Maternal choline intake may influence placental vascular function  
  Previous animal and human studies have shown that choline intake altered the 
transcriptome, leading to changes in pathways related to growth and development, 
methylation and apoptosis (2, 6). Our study is the first to show that choline intake during 
human pregnancy can alter the placental transcript abundance of genes related to vascular 
functioning, including the risk marker of preeclampsia – sFLT1. Consumption of 930 versus 
480 mg choline/d reduced placental sFLT1 expression and circulating maternal sFLT1 
concentrations. Importantly, these results were confirmed in a “proof of principle” study 
employing a human trophoblast cell culture model. These results collectively suggest that a 
maternal choline intake exceeding current recommendations may improve placental function 
and reduce the risk of diseases arising from placental dysfunction including preeclampsia (7).  
 
The response to choline is tissue specific 
 In our feeding study conducted in third trimester pregnancy women, the epigenetic state 
and the transcriptome of the placenta were highly sensitive to maternal choline intake. The 
plasticity of the placental genomic markers in response to maternal nutrition may provide a 
mechanism through which the maternal environment can alter placental function and 
ultimately fetal programming and development (8, 9).  
On the contrary, we did not observe changes in either DNA methylation or gene 
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expression in the peripheral blood leukocytes of the pregnant women within the time frame of 
this study. Thus, unlike the genomic markers of the developing fetal-derived tissues which are 
highly responsive to maternal choline intake (8), genomic markers of the pregnant women 
themselves may be relatively stable to moderate changes in dietary choline intake.   
 
Limitations and future directions 
Our study examined the impact of maternal choline intake during the last third of 
pregnancy only. As most women would consume a prenatal supplement throughout gestation, 
additional studies that administer the supplemental choline from an early timepoint are 
needed. In addition, this thesis examined the “short term” effects of maternal choline intake 
on fetal derived tissues. As epigenetic changes may have long lasting functional effects, 
exploring the long-term functional consequences of these choline-induced alterations is 
warranted. Lastly, as placental angiogenesis starts from early gestation, further studies 
encompassing earlier stages of gestation are needed to more thoroughly understand the 
potential benefits of choline supplementation on maternal vascular health. 
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APPENDIX A 
Choline affects placental development and vascular function in a dose response 
manner* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*This paper has not been submitted for publication. 
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ABSTRACT 
Maternal choline intake during gestation may influence placental function and fetal 
outcome. We previously showed that a choline intake exceeding current recommendations 
during the third trimester of human pregnancy reduced the placental expression of fms-like 
tyrosine kinase-1 (sFLT1), an anti-angiogenic factor and marker of preeclampsia risk. 
Down-regulation of sFLT1 by choline was confirmed in a human trophoblast cell culture 
model.  The current study aimed to quantify the effect of choline on a wider array of 
biomarkers related to trophoblast development and vascular function. Immortalized 
HTR-8/SVneo trophoblasts were cultured in different choline concentrations (28, 13 and 8 
μM) for 96 hours and markers of angiogenesis, inflammation, apoptosis, and blood vessel 
formation were examined. Decreases in choline concentrations led to a graded increases 
(P<0.01) in angiogenic factors [e.g. vascular endothelial growth factor (VEGF)] and in 
proinflammatory markers (e.g., interleukin 1 beta [IL1B]). Diminished choline availability 
(i.e. 8 vs. 28 μM) also induced apoptosis, enhanced oxidative stress, impaired in vitro 
angiogenesis, and increased the protein kinase C (PKC) isoforms δ and ε. These PKC 
isoforms are activated by diacylglycerol, an intermediate of phosphatidylcholine synthesis 
that accumulates under conditions of choline insufficiency. Notably, the addition of a PKC 
inhibitor rescued the impaired angiogenesis, attenuated apoptosis, and partially normalized 
the gene expression profile. In conclusion, choline availability plays an important role in 
trophoblast development and placental vasculature. The influence of choline on the 
trophoblast may be partially mediated by PKC signaling.  
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INTRODUCTION 
Trophoblasts are placental cells of fetal origin which function in nutrient transport, 
immune response and endocrine regulation. Malfunctioning of trophoblast cells leads to 
elevations in inflammation (1), oxidative stress (2), and apoptosis (3), as well as a 
dysregulated angiogenic profile (4, 5). Cytokines and apoptotic debris produced by 
malfunctioning trophoblasts adversely impact adjacent endothelial cells, resulting in 
abnormal placental vasculature (6). The trophoblast induced endothelial dysfunction leads to 
the onset of several pregnancy complications including intrauterine growth restriction (IUGR) 
as well as preeclampsia, a disease characterized by maternal hypertension and proteinuria (6, 
7). Restoring trophoblast function may alleviate the endothelial cell dysfunction of these 
pregnancy complications.  
Choline is an essential nutrient that functions in phospholipid metabolism, 
neurotransmission, and methyl group donation (8). The availability of choline influences 
various biological processes including inflammation (9), apoptosis (10) and angiogenesis (11).  
Our group recently demonstrated that a choline intake exceeding current recommendations of 
450 mg/d reduced placental mRNA expression and maternal circulating concentrations of the 
anti-angiogenic factor and preeclampsia risk marker soluble fms-like tyrosine kinase-1 
(sFLT1) among third trimester pregnant women (12). In addition, a higher maternal choline 
intake (930 versus 480 mg) increased genome-wide and site specific methylation (13), as well 
as acetylcholine concentrations, in the placenta (14). These findings suggest that intrauterine 
choline availability may profoundly influence placental development and vasculature in 
humans.  
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The aim of this study was to analyze the effects of choline on a broader array of 
biomarkers related to trophoblast development and vascular function. Immortalized 
HTR-8/SVneo trophoblast cells were cultured in different choline concentrations and 
readouts of angiogenesis, inflammation, apoptosis, and blood vessel formation were assessed. 
To delineate the mechanism by which choline availability influences trophoblast function, we 
examined the modulatory role of a choline-related signaling pathway (i.e. diacylglycerol and 
protein kinase C [PKC]) on these same biomarkers.  
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MATERIALS AND METHODS 
HTR-8/SVneo cell culture and treatments 
   HTR-8/SVneo is a stable cell line derived from human first trimester placental 
extravillous trophoblast and immortalized with the large T-antigen SV-40 (15). The cells, 
kindly provided by Dr. Charles Graham (Queens University, Kingston, Ontario, Canada), 
were maintained in RPMI1640 culture medium (Mediatech. Inc, Manassas, VA, USA) with 
2mM L-glutamine and 5% fetal bovine serum (FBS) in 5% CO2-95% air at 37⁰C. For 
experiments, customized RPMI1640 medium (Life Technologies, Grand Island, NY, USA) 
which contained no choline, 2mM L-glutamine and 1.25% FBS were used. The FBS provided 
the cells with 8 μM total choline as measured by liquid chromatography- mass spectrometry/ 
mass spectrometry (LC-MS/MS) in our laboratory (14). Choline chloride was added to the 
media to concentrations of 0, 5, 20, 40, and 100μM, yielding total choline concentrations of 8, 
13, 28, 48 and 108 μM, respectively. As standard RPMI1640 medium contains 21μM of 
choline, the range of choline used in the present study was chosen to simulate conditions of 
both choline insufficiency and excess. Cells were seeded in the media containing the different 
choline concentrations at a starting amount of 1.39×106 cells (passages 5-20) per 100×20 mm 
dish. The cells were cultured for 96-h before harvest. The antioxidant N-Acetyl-L-cysteine 
(NAC) (Sigma-Aldrich Corp., St. Louis, MO, USA) was added to the cell culture at 72-h at a 
concentration of 125μM. The tumor protein P53 (TP53) inhibitor pifithrin-α (Cayman 
Chemical, Ann Arbor, Michigan, USA) was added to cell culture at 48-h at a concentration of 
30 μM. To assess the effect of PKC inhibition, 1μM of a broad spectrum PKC inhibitor GF 
109203X (Santa Cruz Biotechnology, Inc, Santa Cruz, CA, USA) was added to the cells at 
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72-h of culture. To inhibit c-JUN N-terminal kinase (JNK), 5μM of the JNK inhibitor 
SP600125 (Fisher Scientific, Pittsburgh, PA, USA) was added at 48-h.  
Human umbilical vein endothelial cells (HUVECs) culture and treatments 
  HUVECs were purchased from Life Technologies and maintained in medium 200 (Life 
technologies) with low serum growth supplements (Life technologies). In vitro angiogenesis 
experiments were performed in cells of less than 16 population doubling.  
Cell count and viability 
Cell counts were performed with a TC10™ automatic cell counter (Bio-Rad, Hercules, CA, 
USA). Cell viability was measured by Trypan blue dye exclusion.  
RNA extraction 
  At 96-h of culture, the attached cells were trypsinized and collected. Total RNA was 
extracted via the commercially available PerfectPure RNA cultured cell kit (5 Prime Inc, 
Gaithersburg, MD, USA). Agarose gel electrophoresis was used to ensure intact ribosomal 
bands in the trophoblast RNA. 
Reverse transcription and quantitative real-time PCR 
Reverse transcription and quantitative real-time PCR were performed as previously 
described (16). All primers were designed using GeneRunner Version 3.01 
(http://www.softpedia.com/) (Supplemental Table SA.1). Data were expressed by the delta 
delta Ct method in which the expression level of the gene of interest was normalized by the 
expression level of housekeeping gene as fold change before comparison between samples 
(17). Beta glucuronidase (GUSB) was used as the housekeeping gene.  
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Choline measurements 
Measurements of the choline derivatives were performed with LC-MS/MS using the 
method described previously (14).  
Membrane fluidity test 
Plasma membrane fluidity was assessed with the fluorescence polarization anisotropy 
value using the dye 1-(4-trimethylammoniumphenyl)-6-phenyl-1,3,5-hexatriene 
p-tolunesulfonate (TMA-DPH) (Marker Gene Technologies, Eugene, OR, USA) which was 
integrated into cellular membranes (18). Attached cells were suspended in a concentration of 
2×105/mL. TMA-DPH dye (2 mM) was added (1mL) to an equal volume of cells and 
incubated at 4oC for 10 min. The anisotropy value was assessed with a PTI 
spectrofluorometer (Photon Technology International, Birmingham, NJ, USA) and calculated 
with the formula r = (IVV-G×IVH)/(IVV+2G×IVH). In this formula, r represents the anisotropy 
value, IVV is the fluorescence intensity recorded with excitation and emission polarization in 
vertical position, IVH is the intensity with excitation in vertical and emission in horizontal 
position, and G is the ratio of sensitivities of the detection system for the vertically and 
horizontally polarized light, with the formula G=IHV/IHH. The lower anisotropy represents the 
higher membrane fluidity.    
Reactive oxygen species (ROS) measurement 
The intracellular ROS was measured with the cell-permeable 
2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA) dye (Cayman) (19). The harvested 
cells were resuspended at a concentration of 1×106/mL and incubated with 4μM H2DCFDA at 
37oC for 45 min. The cells were then centrifuged, resuspended in 1mL PBS and measured 
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with a Coulter Epics XL-MCL flow cytometer (Global Medical Instrumentation, Inc, Ramsey, 
MN, USA) using the FL1 channel.  
Oxidative DNA damage 
Oxidative DNA damage was measured via the alkaline version of single-cell gel 
electrophoresis (the COMET assay) as previously described (20). DNA migration from the 
nucleus after electrophoresis was visualized under a light microscope after staining with 
SYBR Gold fluorescent dye (Life Technologies). Percent tail DNA (defined as the proportion 
of DNA that has migrated from the nucleus) was used as an index of DNA damage and was 
calculated using the software Komet 6.0 (Andor Technology, South Windsor, CT).  
Apoptosis assay 
 Cellular apoptosis was measured with a Multiple Dye Apoptosis assay kit (Cayman) 
according to the manufacturer’s instructions. Briefly, both attached and detached cells were 
collected at 96-h of culture. The FITC-conjugated Annexin V and 7-AAD dyes were added to 
5 ×105 cells in 250μL binding buffer and incubated at room temperature for 15 minutes. The 
cells were centrifuged and resuspended in 500μL binding buffer. The fluorescence intensity 
was measured with flow cytometry. The FITC and 7-AAD signals were detected using the 
FL1 or FL3 channels, respectively. Mitochondria membrane potential was measured using 
the tetramethylrhodamine (TMRE) dye, which was incubated with 5 ×105 cells at 37oC for 30 
min. The fluorescence signals were measured with flow cytometry using the FL2 channel. 
The data was analyzed by the WinMDI 2.9 software (http://www.mybiosoftware.com).  
Western blotting 
  The relative intensity of proteins of interest was measured with western blot assays. For 
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total protein extraction, proteins were extracted with PhosphoSafeTM Extraction Reagent and 
protease inhibitor cocktail set III (EMD Millipore, Billerica, MA, USA). For membrane 
bound protein extraction, the cells were first lyzed by a protein extraction buffer (50mM 
Tris-Cl pH7.5, 150mM NaCl, 1mM EDTA) without adding detergent. The samples were 
centrifuged at 800 × g for 5 min to discard the unlyzed cells and the supernatant was 
transferred to a new microfuge tube and centrifuged at 20000 × g for 30 min. The supernatant 
contained the cytosolic proteins and the pellet contained the membrane-bound proteins. The 
pellet was dissolved in the protein extraction buffer with 2% IPEGAL (Sigma). For nuclear 
protein extraction, a hypotonic buffer was used to make the cells swell, after which 10% 
IPEGAL was applied to lyze the cells for 30 seconds. After centrifuging at full speed for 20 
min, the pellets were resuspended in a nuclear protein extraction buffer. The protein extracts 
were subjected to SDS-PAGE electrophoresis and transferred to polyvinylidene fluoride 
membrane. Primary antibodies used were caspase 3 (CASP3), β-actin, nuclear factor of kappa 
light polypeptide gene enhancer in B-cells (NFKB) 50kDa subunit (Cell Signaling 
Technology, Danvers, MA, USA); and TP53, PKC delta isoform (PRKCD), PKC epsilon 
isoform (PRKCE) and P84 (Gene Tex, Irvine, CA, USA). Primary antibody were added 
overnight at 4oC, after which secondary antibodies, IRDye 800CW Goat Anti Rabbit and 
IRDye 680 Goat Anti mouse (LI-COR, Lincoln, NE, USA), were added. Target protein bands 
were visualized and quantified by the LI-COR Odyssey® imaging system (LI-COR) and 
expressed as the ratio of intensity of a target protein to the reference proteins (β-actin for total 
and membrane-bound proteins and P84 for nuclear proteins).  
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In vitro angiogenesis 
  In vitro angiogenesis was measured with a commercially available kit (Millipore) 
according to manufacturer’s instruction. Briefly, after HTR-8/SVneo cells were cultured in 
RPMI1640 media of differing choline concentrations for 96-h, the cell culture media were 
collected. ECMatrixTM gel was plated in a 96-well tissue culture plate. After the gel was 
solidified, 2 × 104 HUVECs were seeded in each well with 25μL medium 200 with growth 
supplement and 125μL of the RPMI1640 media previously collected. After 12-h, HUVECs 
connected with each other and formed tube- like structures. For each well, 10 random 
view-fields were selected for imaging. Branch points and total capillary tube length were 
measured in these view-fields. The more branch points and longer total capillary tube length 
suggested more vigorous angiogenesis.  
Statistical analysis 
One-way ANOVA followed by post-hoc Bonferroni tests was performed to assess the 
effects of choline treatments. Data not meeting the normality assumption (i.e. residuals were 
normally distributed) were log-transformed. All analyses were performed using SPSS 
(release 18.0 for Windows, SPSS Inc, Chicago, IL). Differences were considered to be 
significant at P ≤ 0.05. Values are presented as means +/- standard error (SE). P-values are 
two-tailed. 
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RESULTS 
Suboptimal choline elevated angiogenic and inflammatory gene expression in the 
HTR-8/SVneo cell culture model 
  At 96-h of culture, HTR-8 cells in the lowest choline concentration (8μM) exhibited a 
lower cell count (P < 0.01) and were more sparsely situated in the culture dishes than the 
other choline groups (13 – 108μM ) which did not differ in cell counts (Figure A.1A-E).  
Markers of cellular proliferation, (mRNA abundance of antigen identified by the monoclonal 
antibody Ki-67 [MKI67]), and cellular differentiation, (mRNA abundance of the β subunit of 
human chorionic gonadotropin [CGB]) did not differ among any of the choline treatment 
groups (Figure A.1F).   
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 Figure A.1. Effects of choline treatment on cell number, proliferation and differentiation of 
the HTR-8/SVneo cells. A- E) Cells were more sparse in the lowest choline group (8μM) than 
the higher choline groups (13-108 μM).  F) mRNA abundance of the proliferation marker 
KI67 and differentiation marker CGB in different choline treatment groups. The 
HTR-8/SVneo cells were cultured in RPMI1640, 2mM L-glutamine and 1.25% fetal bovine 
serum supplemented with five different doses of choline to final total choline concentrations 
of 8 - 108 μM. Cells were cultured at 5% CO2-95% air at 37ºC for 96-h. The same 
experiment was repeated three times. Lowercase letters that differ denote significant 
difference (P < 0.05); NS, not significant. Values are mean ± SE, n=3 per choline treatment 
group per experiment. Data were analyzed with one-way ANOVA followed by post-hoc 
Bonferroni tests.  
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We then measured the mRNA abundance of key angiogenic factors, such as vascular 
endothelial growth factor A (VEGFA). VEGF is an angiogenic factor that mediates normal 
endothelial development and its abundance increases in preeclamptic and IUGR placentas (5, 
21). As choline concentration decreased from 28 to 8 μM in our cell culture model, the 
mRNA abundance of VEGFA increased (P < 0.01) dose dependently (Figure A.2A). We have 
previously reported a similar increase in sFLT1, which is an anti-angiogenic factor and VEGF 
signaling inhibitor, as choline concentrations decreased (12). However, choline 
concentrations greater than or equal to 28μM did not yield significant differences in the 
expression of either gene.  
The results described hereafter focus on the effects of choline treatment concentrations of 8 
to 28 μM on trophoblast function. The groups with lower choline concentrations (i.e. 8 and 
13 μM) were considered to be cultured in environments of suboptimal choline availability 
based on their increased angiogenic factor expression. As key cellular functions such as 
cellular proliferation or differentiation were not affected in either the 8 or 13μM choline 
groups, and the cell count of the 13μM group was not diminished, these two treatment groups, 
8 and 13μM choline, were deemed to represent moderate and mild choline restriction, 
respectively. Choline treatment did not alter mRNA abundance of the pro-angiogenic 
placental growth factor (PGF) (P = 0.12), kinase insert domain receptor (KDR) (P = 0.12), a 
major VEGF receptor (Figure A.2B) or endoglin (ENG) (P = 0.36). Soluble ENG (sENG) is a 
sensitive anti-angiogenic factor, yet its secretion from the HTR-8/SVneo cells was below the 
concentration that can be reliably quantified. However, matrix metalloproteinase 14 (MMP14), 
a proteinase that cleaves ENG and releases sENG under the condition of preeclampsia (22), 
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was upregulated as choline concentrations decreased (Figure A.2B, P < 0.01) indicating a 
route to increase sENG production under conditions of choline insufficiency.  
Choline treatment influenced the mRNA abundance of several proinflammatory markers.  
Increases (P < 0.01) in NFKB1, which encodes the 50kDa subunit of the transcription factor 
NFκB; v-rel reticuloendotheliosis viral oncogene homolog A (RELA), which encodes the 
65kDa subunit of NFκB; and the proinflammatory cytokines interleukin 6 (IL6) and 
interleukin 1, beta (IL1B) with decreases in choline concentration (Figure A.2C). The nuclear 
localization of the 50kDa NFKB1 protein, a sign of NFκB activation, was also elevated as 
choline concentrations decreased (Figure A.2D).   
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Figure A.2. Effects of choline treatment on the expression of angiogenic and 
pro-inflammatory factors in HTR-8/SVneo cells.  A) mRNA abundance of angiogenic 
factors VEGFA and sFLT1 in cells treated with 5 different concentrations of choline 
(8-108μM) for 96-h. B) and C) mRNA abundance of angiogenic factors PGF, ENG, KDR, 
MMP14 and proinflammatory factors NFKB1, RELA, IL6, IL1B in cells treated with 3 
different concentrations of choline (8, 13, 28μM) for 96-h. D) The relative abundance of 
the active NFKB1 protein 50 kDa subunit localized to the nuclear in the 3 different 
choline treatment groups (8, 13, 28μM). Lowercase letters that differ denote significant 
difference (P < 0.05); NS, not significant. Values are mean ± SE, n=3 per choline 
treatment group per experiment. Data were analyzed with one-way ANOVA followed 
post-hoc Bonferroni tests.  
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Suboptimal choline increased trophoblast apoptosis 
One of the consequences of trophoblast dysfunction is cell death. Uncontrolled cell death 
diminishes trophoblast invasion, exacerbates inflammatory cytokine production and leads to 
trophoblast dysfunction and is observed in complicated pregnancies (23). We observed that 
the percentage of cells detached from the culture dish increased (P < 0.01) dose dependently 
as choline concentrations decreased (Figure A.3A). These data suggest that deprivation of 
choline in culture medium inhibited the growth and/or increased trophoblast apoptosis. We 
then examined whether apoptosis and/or necrosis occurred in these trophoblasts under the 
condition of suboptimal choline concentrations. Apoptosis was analyzed with annexin 
V/7-AAD staining and flow cytometry combining the attached and detached cells. The 
percentage of annexin V positive and 7-AAD negative cells which indicates early apoptosis 
did not differ (P = 0.39) among the choline treatment groups, whereas the percentage of 
annexin V and 7-AAD positive cells which indicates late apoptosis or necrosis increased (P < 
0.01) dose dependently as choline concentrations lowered (Figure A.3B-E). Lowering choline 
concentrations led to a dose response loss (P < 0.01) in mitochondria potential, as 
demonstrated by the negative staining of the mitochondria specific TMRE dye (Figure 
A.3F-G). The mRNA abundance of the apoptosis executor CASP3 increased (P < 0.01) in the 
lower versus high choline group (Figure A.5H). Western blotting also detected a dose 
response increase in cleaved CASP3, a sign of CASP3 activation, in the lower choline groups 
(Figure A.3H-I), which confirmed the induction of apoptosis by the suboptimal choline 
concentrations.  
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Figure A.3. Effects of choline treatment on cell death of the HTR-8/SVneo cells.  A) 
Percent cells detached from the dishes after choline treatments (8, 13, 28μM) for 96-h. B) 
- E) Cellular apoptosis in the three choline treatment groups. Both attached and detached 
cells were collected at 96-h of culture. Annexin V positive and 7-AAD negative cells 
were early apoptotic; anexin V and 7-AAD positive cells were late-apoptotic/ necrotic. F) 
Relative fluorescence intensity of TMRE dye in the three choline groups. Red line, 28μM 
choline; blue line,13μM choline; grey shape, 8μM choline. G) Mitochondria potential of 
attached cells. H) CASP3 mRNA abundance and active cleaved CASP3 protein 
abundance in the three choline groups. I), Example western blotting of CASP3 species. 
Lowercase letters that differ denote significant difference (P < 0.05); NS, not significant. 
Values are mean ± SE, n=3 per choline treatment group per experiment. Data were 
analyzed with one-way ANOVA followed by post-hoc Bonferroni tests.  
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As P53 activation is often involved in the apoptotic process, we examined mRNA 
abundance and protein concentrations of TP53, both of which were higher (P < 0.05) in the 
lower choline groups (Figure A.4A-B). However, the addition of a P53 inhibitor (pifithrin-α) 
did not resolve apoptosis (Figure A.4C), despite that P53 inhibition rescued/partially rescued 
the increase in mRNA abundance of IL6, P53, VEGF and IL1B (Figure A.4D).  
 
  
 
Figure A.4. P53 activation and the effects of addition of the P53 inhibitor pifithrin-α on 
the three choline treatment groups (8, 13, 28μM). A) mRNA abundance and B) 
intracellular protein levels of P53. C) Percent apoptotic cells after the addition of P53 
inhibitor pifithrin-α 30μM after 48-h of culture. D) mRNA abundance of angiogenic and 
proinflammatory genes after the addition of piththrin-α. Lowercase letters that differ 
denote significant difference (P < 0.05); NS, not significant. Values are mean ± SE, n=3 
per choline treatment group per experiment. Data were analyzed with one-way ANOVA 
followed by post-hoc Bonferroni tests.  
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Suboptimal choline inhibited in vitro angiogenesis 
  It has been proposed that dysregulated trophoblast cytokine secretion and apoptosis impair 
normal endothelial cell functioning, thereby inhibiting angiogenesis (6). To examine whether 
the difference in choline concentrations and the secretory profiles of the HTR-8 cells affect 
angiogenesis, the culture media obtained from different choline treatment groups at 96-h of 
HTR8 culture were incubated with HUVECs seeded on matrix gels. The 8μM choline group 
had significantly lower (P < 0.01) endothelial tube branching and shorter (P < 0.01) total tube 
length, which indicate impaired angiogenesis, compared to the higher choline groups (Figure 
A.5 A-D). These results confirmed that suboptimal choline availability impaired endothelial 
function. 
 
  
 
137 
 
  
Figure A.5. Influence on in vitro angiogenesis of HTR8S/SVneo cells in the three choline 
treatment groups (8, 13, 28μM). A)- C) Development of endothelial tube networks in 
HUVEC cells. After HTR-8/SVneo cells were cultured in RPMI1640 media of different 
choline concentrations for 96-h, the cell culture media were collected. ECMatrixTM gel 
was plated in a 96-well tissue culture plate. After the gel was solidified, 2 × 104 HUVECs 
were seeded in each well with 25μL medium 200 with growth supplement and 125μL of 
the RPMI1640 media previously collected. After 12-h, the tube formation network was 
viewed. D). Branch points and tube lengths of HUVEC cells incubated with media from 
different HTR8 choline treatment groups. Lowercase letters that differ denote significant 
difference (P < 0.05); NS, not significant. Values are mean ± SE, n=3 per choline treatment 
group per experiment. Data were analyzed with one-way ANOVA followed by post-hoc 
Bonferroni tests.  
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Suboptimal choline altered phosphatidylcholine metabolism 
  To delineate through which pathway(s) choline treatment influences trophoblast function, 
we measured the alterations in choline metabolite concentrations and gene expression 
(Figure A.6A). Lowering choline concentrations in culture media led to a decrease (P < 0.01) 
in the concentrations of phosphatidylcholine, glycerophosphocholine, phosphocholine, and 
free choline (Figure A.6B-G). However, betaine and sphingomyelin concentrations were not 
altered (P = 0.4 - 0.6) and acetylcholine was not detected in the HTR8/SVneo cells.  
   The decrease in choline availability led to higher (P < 0.01) expression of 
phosphatidylethanolamine N-methyltransferase (PEMT), the gene encoding the enzyme that 
mediates de novo phosphatidylcholine synthesis (Figure A.6H). Choline kinase, isoform 
alpha (CHKA) and phosphate cytidylyltransferase 1, choline, alpha (PCYT1A), the genes 
encoding enzymes for the CDP-choline pathway of phosphatidylcholine synthesis were also 
higher (P < 0.05) in the lowest (8μM) versus the highest (28μM) choline group. Choline 
dehydrogenase (CHDH), which oxidizes choline to betaine, was not altered. Betaine 
homocysteine S-methyltransferase (BHMT), which donates a methyl group from betaine to 
remethylate homocysteine, was not expressed in these cells (data not shown). These data 
collectively show that when choline is limited, the cells engage mechanisms to compensate 
for diminished phosphatidylcholine by upregulating the enzymes in both pathways of 
phosphatidylcholine synthesis.  
  
139 
 
  
Figure A.6. Effects of choline treatment on choline metabolism in the HTR-8/SVneo 
cells.  A) choline metabolic pathways and key enzymes in trophoblasts. Abbreviations: 
CHDH, choline dehydrogenase; CK, choline kinase (encoded by CHKA); CT, phosphate 
cytidylyltransferase encoded by (PCYT1A); GPC, glycerophosphocholine; PC, 
phosphatidylcholine; PCHO, phosphocholine; PE, phosphatidylethanolamine; PEMT, 
phosphatidylethanolamine methyltransferase; SAM, S-adenosylmethionine. B) - F) 
Intracellular concentrations of choline metabolites in HTR8/SVneo cells treated with 3 
different choline concentrations (8, 13, 28μM) for 96-h. H) The mRNA abundance of 
choline metabolic enzymes in the three choline treatment groups. Lowercase letters that 
differ denote significant difference (P < 0.05); NS, not significant. Values are mean ± SE, 
n=3 per choline treatment group per experiment. Data were analyzed with one-way 
ANOVA followed by post-hoc Bonferroni tests. 
 
140 
 
The altered phosphatidylcholine metabolism may increase cellular membrane fluidity and 
ROS production 
  Disrupted metabolism of choline derived phospholipids (e.g. phosphatidylcholine) has 
been shown to decrease cellular membrane integrity (i.e., increased membrane fluidity), 
which increases the mitochondrial leakage of ROS in hepatocytes (24, 25). ROS leakage 
causes oxidative stress, which is a known stimulator of anti-angiogenic factor production and 
apoptosis in trophoblasts (26, 27). We examined the membrane fluidity and ROS production 
in the HTR-8/SVneo cells treated with different concentrations of choline. Cellular 
membrane anisotropy was used as a marker of membrane fluidity, and the higher anisotropy 
indicates lower membrane fluidity. The anisotropy value was lower (P = 0.02) in the 8 versus 
28μM choline group, suggesting elevated membrane fluidity under the condition of 
suboptimal choline concentrations (Figure A.7A). Consistently, intracellular ROS increased 
(P < 0.01) as the choline concentrations in the cell culture media decreased (Figure A.7B). As 
a consequence, oxidative DNA damage increased (P < 0.01) dose dependently as choline 
concentrations lowered (Figure A.7C). These results confirmed that lowering choline 
availability diminished membrane integrity and increased oxidative stress in the 
HTR-8/SVneo cells. However, adding the antioxidant NAC to the 8μM choline group during 
cell culture did not resolve either the increased intracellular ROS or angiogenic and 
proinflammatory gene expression (Figure A.7D and E).  
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Figure A.7. Effects of choline treatment and the addition of the antioxidant NAC on 
membrane fluidity and oxidative stress markers in the HTR-8/SVneo cells.  A) 
Membrane fluidity of cells cultured in 3 different choline concentrations (8, 13, 28μM) 
for 96-h. Cells were incubated with 2mM TMA-DPH dye at 4oC for 10 min and 
fluorescence anisotropy was measured with a fluorometer. The higher anisotropy 
represents lower membrane fluidity.  B) Intracellular production of ROS in the three 
choline treatment groups. Cells were collected and incubated with 4μM H2DCFDA at 
37oC for 45 min. Fluorescence was measured by a flow cytometer. C) DNA damage of 
the three choline treatment groups measured by the Comet assay. The higher DNA 
damage suggests higher oxidative stress. D) Intracellular production of ROS and E) 
mRNA abundance of VEGF, NFKB1 and TP53 after the addition of the antioxidant NAC 
125μM at 72-h of culture in the lowest (8μM) choline group. Lowercase letters that differ 
denote significant difference (P < 0.05); NS, not significant. Values are mean ± SE, n=3 
per choline treatment group per experiment. Data were analyzed with one-way ANOVA 
followed by post-hoc Bonferroni tests. 
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The JNK/c-Jun pathway is a potential mediator of intracellular ROS production, as 
previous studies suggest that the mitogen activated protein kinase (MAPK) JNK activates the 
jun proto-oncogene (JUN), which can subsequently bind to DNA and modulate the 
transcription of an array of genes (e.g., VEGF (28), and is involved in P53 activation and 
ROS generation (29). Thus, we examined the mRNA abundance of JNK and JUN, both of 
which increased (P < 0.01 for JNK and P = 0.05 for JUN) under conditions of reduced 
choline concentrations (Figure A.8A and B). The phosphorylation of JNK at Tyr183 and 185 
is required for the activation of this MAPK. We found that phosphorylated JNK 
concentrations increased (P < 0.01) in the lower choline treatment groups, consistent with 
JNK activation (Figure A.8C). The addition of the JNK inhibitor SP600125 at 48-h of culture 
resolved the increased ROS production (Figure A.8D). However, JNK inhibition did not 
resolve apoptosis (data not shown) and did not improve the gene expression profile, except 
for IL1B (Figure A.8E). These results suggest that rescuing the oxidative stress alone cannot 
normalize the adverse consequences induced by suboptimal choline concentrations and that 
other upstream mechanisms may be involved. 
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Figure A.8. Effects of the JNK/s-JUN pathway on the HTR8/SVneo cells treated with 3 
different concentrations of choline (8 and 13 μM). A) and B), mRNA abundance of JNK 
and JUN in the choline treatment groups. C) relative abundance of the phosphorylated 
JNK. D), intracellular production of ROS and mRNA abundance after the addition of the 
JNK inhibitor SP600125 of 5μM at 48-h. Lowercase letters that differ denote significant 
difference (P < 0.05); NS, not significant. Values are mean ± SE, n=3 per choline 
treatment group per experiment. Data were analyzed with one-way ANOVA followed by 
post-hoc Bonferroni tests.  
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The activation of PKCs might contribute to the trophoblast dysfunction related to suboptimal 
choline availability 
   Previous studies in mice have shown that a choline deficient diet elevated intermediates 
of phosphatidylcholine synthesis, such as diacylglycerol (DAG), which are major activators 
of PKCs (30, 31). As the PKCs have been shown to regulate angiogenic genes (32), ROS 
production (33) and apoptosis (31), we examined whether the altered expression of PKC was 
involved in the trophoblast dysfunction induced by suboptimal choline availability. The 
mRNA abundance of the DAG regulated PKC δ and ε isoforms (PRKCD and PRKCE) both 
increased (P < 0.01) in the low choline group (8μM) (Figure A.9A and B). On the contrary, 
the non-DAG regulated atypical PKC ξ (PRKCZ) was not altered by choline treatment (P = 
0.33) (Figure A.9C). As the activation of PKCs involves the translocation of the enzymes to 
the cellular membrane, we then measured the cytosolic and membrane-bound PRKCD and E 
protein concentrations. Consistent with the mRNA abundance, PRKCE increased under 
suboptimal choline environments both in the cytosolic and the membrane fractions (Figure 
A.9D). However, PRKCD protein concentrations were not altered in the choline treatment 
groups in either cellular fractions (Figure A.9E).  
Adding a PKC inhibitor GF109203X resolved the heightened apoptosis (Figure A.10A) 
and impaired in vitro angiogenesis of the lowest choline group (8μM) (Figure A.10B). This 
inhibitor also partially resolved the increased mRNA abundance of sFLT1, IL1B and TP53 
(Figure A.10C), and secretion of sFLT1 to cell culture medium (Figure A.10D).  
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Figure A.9. The activation of PKCs in the HTR8/SVneo incubated in three choline 
concentrations (8, 13, 28μM) for 96-h. A) - C) mRNA abundance of PRKCD, PRKCE 
and PRKCZ of the three choline treatment groups at 96-h of culture. D) and E) cytosolic 
and membrane bound protein abundance of PRKCD and PRKCE in the three choline 
treatment groups. Lowercase letters that differ denote significant difference (P < 0.05); 
NS, not significant. Values are mean ± SE, n=3 per choline treatment group per 
experiment. Data were analyzed with one-way ANOVA followed by post-hoc 
Bonferroni tests. 
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  Figure A.10. PKC inhibition rescued some adverse consequences induced by 
suboptimal choline concentrations (8 and 13 μM) in culture of the HTR8/SVneo cells.. 
A) Apoptosis, B) in vitro angiogenesis, C) mRNA abundance and  D) sFLT1 secretion 
after the addition of the broad brand PKC inhibitor GF 109203X. The 1μM of GF 
109203X was added to the cells at 72-h of culture. Lowercase letters that differ denote 
significant difference (P < 0.05); NS, not significant. Values are mean ± SE, n=3 per 
choline treatment group per experiment. Data were analyzed with one-way ANOVA 
followed post-hoc Bonferroni tests.  
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DISCUSSION 
This study investigated the influence of choline availability on trophoblast functioning. 
Our results show that mild to moderate choline restriction in the HTR-8/SVneo trophoblast 
culture model did not affect cellular proliferation and differentiation, yet resulted in 
trophoblast dysfunction, as demonstrated by increased expression of angiogenic and 
proinflammatory genes, heightened oxidative stress, apoptosis and/or necrosis, which 
subsequently led to impaired endothelial angiogenesis. These choline mediated effects were 
partially resolved by inhibiting PKC, suggesting the involvement of the phospholipid 
signaling pathway.  
 
Suboptimal choline resulted in trophoblast dysfunction and impaired angiogenesis 
A common characteristic of placentas from preeclamptic and IUGR pregnancies is 
abnormal trophoblast production of angiogenic factors such as VEGF, sFLT1, sENG and PGF 
(21, 34). The increased trophoblast secretion of anti-angiogenic factors (e.g. sFLT1 and sENG) 
sequesters placental and maternal endothelial growth factors (e.g. VEGF), resulting in 
vascular dysfunction (7, 35). In our cell culture model, VEGFA, a vascular factor that 
mediates blood vessel development, increased as choline concentrations in the culture 
decreased. The upregulation of VEGFA is consistent with observations in preeclamptic 
placentas, and may be an attempt of the stressed placenta to counter endothelial dysfunction 
and placental ischemia (21). sENG and sFLT1 are two major anti-angiogenic factors, which 
inhibit normal vascular development and are upregulated in preeclampsia(27). We previously 
found that sFLT1 increased as choline concentrations decreased (12). Although ENG 
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transcript was not altered in the present study, the increase in MMP14 which converts ENG to 
the anti-angiogenic sENG, suggests its potential inhibitory effect on angiogenesis. Overall, 
the altered angiogenic panel under conditions of suboptimal choline is consistent with a shift 
towards an anti-angiogenic profile which may adversely affect angiogenesis.  
Enhanced inflammation is another manifestation of trophoblast dysfunction (36-38). In 
our study, transcripts of several pro-inflammatory markers (i.e., IL1B, IL6, NFKB1 and RELA) 
were increased. The higher nuclear localization of the P50 subunit of NFKB1 in the 
suboptimal choline groups is also consistent with activation of proinflammatory pathways. It 
may also reflect a compensatory attempt of the cells to prevent choline deficiency induced 
apoptosis (39). 
In addition to the transcriptional responses, reducing choline availability also led to cell 
death which appeared to involve both apoptosis and necrosis. Although apoptosis is a normal 
phenomenon which occurs during trophoblast development, uncontrolled apoptosis that turns 
into necrosis (i.e. aponecrosis) can result in the release of “uncoated” cell debris to adjacent 
tissues and maternal circulation, which triggers a systemic inflammatory response and 
endothelial dysfunction (3). The higher proportion of late apoptotic/necrotic cells and the 
presence of activated apoptosis executor CASP3 observed in the low choline groups indicate 
that reducing choline resulted in aponecrosis.  
The in vitro angiogenesis assay confirms that the disturbance in trophoblast functioning 
due to suboptimal choline availability eventually impaired the angiogenic process of 
endothelial cells. Taken together, these data suggest that suboptimal choline availability may 
influence the development of pregnancy complications by adversely affecting trophoblast 
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functioning and placental vasculature.   
 
PKC signaling may be involved in the suboptimal choline induced trophoblast dysfunction  
The mechanism by which choline affects trophoblast functioning and angiogensis is 
ill-defined. In the current study, several choline metabolites related to phosphatidylcholine 
synthesis were diminished in a suboptimal choline environment. The impact of 
phosphatidylcholine on trophoblast functioning can be exerted via disturbance in membrane 
integrity, which leads to increased oxidative stress (25). Although both diminished plasma 
membrane integrity and increased oxidative stress were observed as choline concentrations 
decreased, neither the addition of an antioxidant NAC nor rectifying oxidative stress by a 
JNK inhibitor restored the cytokine expression profile or inhibited cell death, suggesting that 
oxidative stress may be a downstream, rather than an upstream, consequence of choline 
inadequacy.  
Phosphatidylcholine may also influence trophoblast functioning via phospholipid 
signaling. Previous studies have shown that choline deficiency leads to an increase in DAG, 
an intermediate of the CDP-choline pathway as well as a by-product of phosphatidylcholine 
catabolism (40, 41). The gene expression profile of the choline metabolizing enzymes in the 
present study is most consistent with accumulation of DAG in an attempt to synthesis more 
phosphatidylcholine via the CDP-choline pathway. The increase in DAG can activate PKCs, 
a group of proteins that are involved in multiple signaling pathways. The PKCs are 
functionally diverse; some isoforms promote growth (e.g. PRKCA, PRKCE) while other 
isoforms are either pro-apoptotic or have mixed effects on survival (e.g. PRKCD, PRKCZ) 
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(31, 42). We detected that both PRKCD and E were increased as choline concentrations 
decreased. For PRKCE, membrane localization increased, which is a sign of activation. 
Importantly, after we applied a PKC inhibitor, both apoptosis and the inhibitory effects of 
choline insufficiency on angiogenesis were completely rescued and trophoblast dysfunction 
was alleviated. The restoration of trophoblast function by inhibiting PKC suggests that 
phospholipid and PKC signaling is an important route through which choline is involved in 
placental development and vasculature.  As such, PKC may serve as a molecular target for 
diagnosis and treatment (via inhibition) of placental related complications. However, it 
should be noted that not all aspects of trophoblast function were rescued by the inhibition of 
PKCs. Additional studies which further delineate the complex signaling network regulated by 
choline availability in trophoblasts are warranted.  
 
Conclusion 
In conclusion, our study revealed the importance of adequate choline nutrition for 
maintaining normal placental trophoblast function and preventing its adverse influence on the 
endothelial system. Additional studies are needed to more fully delineate the mechanism by 
which choline availability impacts trophoblast functioning. Studies are also needed to explore 
the clinical efficacy of choline supplementation in reducing the risk of pregnancy 
complications that arise from impaired placental function and vascularization.  
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Supplemental Table SA1. Primers used for quantitative real-time PCR 
Gene symbol Forward primer Reverse primer 
BGUS 5' CTCTTGGTATCACGACTACGGG 3' 5' CAATCGTTTCTGCTCCATACTC 3' 
BHMT 5' CGTGGACTTCTTGATTGCAG 3' 5' AATCTCCTTCTGGGCCAATG 3' 
CASP3 5’TAAAATACCAGTGGAGGCCG 3’  5’ GCACAAAGCGACTGGATGAA 3’  
CASP3 5’TAAAATACCAGTGGAGGCCG 3’  5’ GCACAAAGCGACTGGATGAA 3’  
CGB 5’ TGCATCACCGTCAACACCAC 3’ 5’ AGTTGCACACCACCTGAGGC 3’  
CHDH 5' GCAAGGAGGTGATTCTGAGTGG 3' 5' GGATGCCCAGTTTCTTGAGGTC 3' 
CHKA 5’ GCGAGGACGAGTTCCACATC 3’ 5’ CATACAGCCGCAGGAGCACT 3’ 
CTA 5' CAGAAGGTGGAGGAAAAAAGCA 3' 5' TATGTTTCAGTGCTCCTTCCGG 3' 
IL1B 5’ GCTGGAATTTGAGTCTGCCC 3’ 5’ ACAAATTGCATGGTGAAGTCAG 3’  
IL6 5’ CATGTGTGAAAGCAGCAAAGAG 3’  5’ GATTTTCACCAGGCAAGTCTCC 3’ 
JNK 5’ TCTTCCCTGATGTCCTTTTCC 3’  5’ ACGGGTGTTGGAGAGCTTCAT 3’ 
JUN 5’ AAAAGGAAGCTGGAGAGAATCG 3’ 5’ TCTGTTTAAGCTGTGCCACCTG 3’ 
KDR 5’ TTGTACACCTGTGCAGCATCC 3’ 5’ GCTTCCACCAGAGATTCCATG 3’ 
KI67 5’ AGTACATGTGCCTGCTCGACC 3’ 5’ TGCTCCTTCACTGGGGTCTTG 3’  
NFKB1 5’ GCTGCCAAAGAAGGACATGATA 3’ 5’ AGGCTATTGCTCATCATGGCTA 3’ 
PEMT 5' GGGGTTCGCTGGAACTTTC 3' 5' GCCCAGGTAGTTGGCTGTG 3' 
PGF 5' TATTAGCCAACTGTTTCCCTGC 3’   5' GGCTGGCTTCTCTCTTTCTCTCA 3’ 
PRKCD 5’ ACCTTCTGTGACCACTGCGG 3’  5’ CCACCTTCTCCCGGCATTTA 3’ 
PRKCE 5’ GCCACGAGCTCATAATCACAAA 3’ 5’ TTGTGGATACCGAACTTGTGGG 3’ 
PRKCZ 5' AGAGCTGGTGCATGATGACGA 3' 5' AATGACCAGGAACAACCGACT 3' 
RELA   5’ GTGAACCGAAACTCTGGCAG 3’ 5’ AGCCTGGTCCCGTGAAATAC 3’ 
sFLT1 5' AGGGGAAGAAATCCTCCAGAAG 3'  5' GTGGTACAATCATTCCTTGTGCT 3' 
TP53 5’ AGTGTGGTGGTGCCCTATGAG 3’  5’ TGTGATGATGGTGAGGATGGG 3’  
VEGF 5'AGACCTGGTTGTGTGTGTGTGA 3’ 5' TCTCTTTTCTCTGCCTCCACAA 3’ 
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APPENDIX B 
Copy right approval forms 
 


